Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of [COMPANY_011] (or any of its 
affiliated companies). The use of such confidential information must be re stricted to the recipi[INVESTIGATOR_21321], published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of [COMPANY_011] (or the concerned affilia ted company); ‘affiliat ed company’ means any corporatio n, partnership or other entit y which at the date 
of communication or afterwards (i) controls directly or indirectly [COMPANY_011], (ii) is directly or indirectly controlled by [CONTACT_13225],  with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capi[INVESTIGATOR_13040], partnership or oth er entity 
According to template: Version [COMPANY_011] dated 12-SEP-2017 based on TransCelerate CPT version 4 Page 1 AMENDED CLINICAL TRIAL PROTOCOL 01   
Protocol title: A randomized, doubl e-blind, placebo-controlled, 
parallel-group, Proof-of-Concept (PoC) study to assess 
the efficacy, safety and tolerability of SAR440340, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) 
Protocol number: ACT15104 
Amendment number: 01 Compound number 
(Trademark/INN): SAR440340/REGN3500 
Short title: Proof-of-Concept study to assess the efficacy, safety 
and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) 
Sponsor name: 
[CONTACT_245668]: 
Regulatory agency identifying number(s): 
EudraCT number: 2017-003290-34 
IND number: 134401 
UTN number: Not yet available 
Approval Date: 11-Jun-2018 Total number of pages: 113 
(electronic 1.0)[STUDY_ID_REMOVED]
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 2 
 Sponsor signatory:  
Please refer to the last page of this document for electronic signatures including date and time 
 
Monitoring Team’s Representative 
Name [CONTACT_9352] [CONTACT_7171]:  
 
 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 3 
 PROTOCOL AMENDMENT SUMMARY OF CHANGES 
DOCUMENT HISTORY 
 
Document Country/countries 
impacted by 
[CONTACT_208514], version 
Amended Clinical Trial Protocol 01 All 11-Jun-2018, Version 1 (electronic 1.0) 
Original Protocol  
30-Mar-2018, Version 1 (electronic 2.0) 
Amended protocol [01] (Day Month Year) 
This amended protocol (Amendmen t 01) is considered to be non -substantial based on the criteria 
set forth in Article 10(a) of Di rective 2001/20/EC of the European  Parliament a nd the Council of 
the European Union.  
OVERALL RATIONALE FOR THE AMENDMENT 
This amendment incorporates recommendation from the European Union clinical trial review. 
Protocol amendment summary of changes table 
Section # 
and Name [CONTACT_23688] 
1.3.1 
Schedule of Activities  Footnote added to blood  eosinophils and neutrophils to specify that a complete hematology panel will be performed at Visit 4, Visit 12 and 
follow-up Visit F1  Clarification for the biomarker (blood eosinophils and 
neutrophils) collection visits is provided in order to address the request from the Health Agencies review.  
4.3 Justification 
for Dose  Details added to the justification for dose  Requested during the Health Agencies review of the 
clinical trial application. 
5.2 Exclusion Criteria  Deleted E08: Participants with COPD diagnosed within the 6 months prior to randomization  During the Health Agencies' review of the clinical trial application, an inconsistency was identified in the 
duration of COPD diagnosis required for study inclusion. As per inclusion criterion I01, patients with a diagnosis of 
COPD for at least [ADDRESS_1225979] 1 year, therefore E08 is now 
deleted. 
 Modified E26: Known allergy to doxycycline or 
related compounds. Per the Healthy Agencies' request, the criterion is being 
modified to also exclude patients with a history of 
systemic hypersensitivity to any excipi[INVESTIGATOR_31625]. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 4 
 Section # 
and Name [CONTACT_877393] E34: Patients with cardiovascular 
diseases/conditions:  for uncontrolled hypertension Per the Health Agencies' reques t, the exclusion criterion 
related to uncontrolled hypertension has been modified in 
order to exclude patients with grade 3 hypertension (high cardiovascular risk). 
6.5 Concomitant Therapy Removed intra-articular steroids from permitted concomitant therapy Resolve an inconsistency as relevant systemic exposure may occur with intra-articular steroids. Systemic steroids 
are not permitted during the screening or treatment 
phases. 
[IP_ADDRESS] COPD exacerbation Added “Any course of systemic steroids/antibiotics started <7 days of finishing a previous course 
should be considered as treatment for a single exacerbation” Further clarification has been provided as regards 
reporting of COPD exacerbations. 
8.1.2 Patient 
reported outcomes 
questionnaires Added “Record use of systemic corticosteroids 
and/or antibiotics taken for COPD exacerbation” An inconsistency between set-up of e-diary and the protocol e-diary language has been corrected. 
Section 10.10 
- Appendix 10 Added Appendix 10  and renumbered other appendices This is the appendix for Protocol Amendment History 
All sections Minor inconsistencies corrected, spelling and 
grammar corrected Improve the quality of the document 
 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: [ADDRESS_1225980] OF FIGURES.......................................................................................................................................... 9 
1 PROTOCOL SUMMARY ............................................................................................................... 10 
1.1 SYNOPSIS..................................................................................................................................... 10 
1.2 SCHEMA........................................................................................................................................ 16 
1.3 SCHEDULE OF ACTIVITIES (SOA) ............................................................................................. 17 
1.3.1 Schedule of Activities (SoA) for Patients who complete the Planned Treatment .......................... 17 
1.3.2 Schedule of Activities (SoA) for Patients After Early Treatment Discontinuation .......................... 21 
2 INTRODUCTION............................................................................................................................ 24 
2.1 STUDY RATIONALE................................................................................................................ ......24 
2.2 BACKGROUND ..................................................................................................................... ........ 24 
Chronic obstructive pulmonary disease .......................................................................................... .............. 24 
SAR440340 - Anti-IL-33 monoclonal antibody ..................................................................................... ......... 25 
2.3 BENEFIT/RISK ASSESSMENT..................................................................................................... 26 
3 OBJECTIVES AND ENDPOINTS ................................................................................................. 27 
3.1 APPROPRIATENESS OF  MEASUREMENTS .............................................................................. 29 
4 STUDY DESIGN ................................................................................................................... ......... 30 
4.1 OVERALL DESIGN................................................................................................................. .......30 
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN......................................................................... 31 
4.3 JUSTIFICATION FOR DOSE ........................................................................................................ 32 
4.4 END OF STUDY DEFINITION....................................................................................................... 32 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 6 
 5 STUDY POPULATION ............................................................................................................... ...33 
5.1 INCLUSION CRITERIA............................................................................................................. .....33 
5.2 EXCLUSION CRITERIA ............................................................................................................... 34 
5.3 LIFESTYLE CONSIDERATIONS................................................................................................... 38 
5.4 SCREEN FAILURES...................................................................................................................... 38 
6 STUDY INTERVENTION ............................................................................................................... 40 
6.1 STUDY INTERVENTION(S) ADMINISTERED.............................................................................. [ADDRESS_1225981](S).......................................................................................... [ADDRESS_1225982](S).................................................................................. 41 
6.2 PREPARATION/HANDLING/ST ORAGE/ACCOUNTABILITY....................................................... 43 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING ....................................... 44 
6.3.1 Methods of assigning pati ents to treatment group......................................................................... 44 
6.3.2 Methods of blindi ng........................................................................................................................ 45 
6.3.3 Randomization code breaking during the study............................................................................. 46 
6.4 STUDY INTERVENTION COMPLIANCE ...................................................................................... 46 
6.5 CONCOMITANT THERAPY .......................................................................................................... 46 
6.6 DOSE MODIFICATION.............................................................................................................. ....47 
6.7 INTERVENTION AFTER THE END OF THE STUDY................................................................... 47 
7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ........................................................................................... 48 
7.1 DISCONTINUATION OF STUDY INTERVENTION ..................................................................... 48 
7.1.1 Permanent disc ontinuation ...................................................................................................... ......48 
7.1.2 Temporary discontinuation...................................................................................................... .......50 
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY.................................. [ADDRESS_1225983] TO FOLLOW UP .............................................................................................................. ...51 
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................................... 52 
8.1 EFFICACY ASSESSMENTS ........................................................................................................ 52 
8.1.1 Disease-specific efficacy measures............................................................................................. ..52 
8.1.2 Patient reported outco mes questionnaires .................................................................................... 54 
8.2 SAFETY ASSE SSMENTS ............................................................................................................ 56 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: [ADDRESS_1225984].............................................................................................. .....58 
8.3.2 Time period and frequency for colle cting AE and SAE information............................................... 62 
8.3.3 Method of detecti ng AEs and SAEs............................................................................................... 63 
8.3.4 Follow-up of AEs and SAEs........................................................................................................... 63 
8.3.5 Regulatory reporting requirement s for SAEs ................................................................................. 63 
8.3.6 Pregnancy ...................................................................................................................................... 63 
8.3.7 Disease-related events and/or disease-related outcomes not qualifying as AEs or SAEs ........... [ADDRESS_1225985] complaints / medical device incidents (including 
malfunctions).................................................................................................................. ................ 64 
8.4 TREATMENT OF  OVERDOSE...................................................................................................... 64 
8.5 PHARMACOKINETICS.................................................................................................................. 64 
8.6 PHARMACODYNAMICS ............................................................................................................... 66 
8.6.1 Pharmacodynamic variables/Biomarkers....................................................................................... 66 
8.6.2 Whole blood bi omarkers ................................................................................................................ 66 
8.6.3 Plasma/serum biomarkers ........................................................................................................ .....66 
8.7 PHARMACOGENOMICS............................................................................................................... 67 
8.8 BIOMARKERS ............................................................................................................................... 67 
8.8.1 Immunogenicity assessments........................................................................................................ 67 
8.9 HEALTH ECONOMICS.................................................................................................................. 68 
9 STATISTICAL CONSIDERATIONS ............................................................................................. 69 
9.1 STATISTICAL HYPOTHESES....................................................................................................... 69 
9.2 SAMPLE SIZE DETERMINATION ................................................................................................ 69 
9.3 POPULATIONS FOR ANALYSES................................................................................................. 71 
9.4 STATISTICAL ANALYSES ........................................................................................................... .71 
9.4.1 Efficacy analyses .............................................................................................................. ............. 71 
9.4.2 Safety analyses................................................................................................................ .............. 73 
9.4.3 Other analyses ............................................................................................................................... 74 
9.5 INTERIM ANALYSES .............................................................................................................. .....75 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 8 
 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS ........................ 76 
10.1 APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS....... 76 
10.1.1  Regulatory and Ethica l Consider ations.......................................................................................... 76 
10.1.2  Informed Consent Process ....................................................................................................... .....76 
10.1.3  Data Protection ................................................................................................................ .............. 77 
10.1.4  Committees Structure .................................................................................................................... 77 
10.1.5  Dissemination of Clin ical Study Data........................................................................................... ..77 
10.1.6  Data Quality Assurance ......................................................................................................... ........ 78 
10.1.7  Source documents ............................................................................................................... .......... 78 
10.1.8  Study and Site Closure ......................................................................................................... ......... 78 
10.1.9  Publicatio n Policy........................................................................................................................... 79 
10.2 APPENDIX 2: CLINICAL LABORATORY TESTS ......................................................................... 79 
10.3 APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING ................................................ 80 
10.4 APPENDIX 4: CONTRACEPTIVE GUIDAN CE AND COLLECTION OF PREGNANCY 
INFORMATION.............................................................................................................................. 85 
10.5 APPENDIX 5: PHARMACOGENOMICS ....................................................................................... 88 
10.6 APPENDIX 6: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND FOLLOW-UP ASSESSMENTS ................................................................................................................... ........ 89
 
10.7 APPENDIX 7: LIST OF PROHIBIT ED LIVE ATTENUATED VACCINES...................................... 94 
10.8 APPENDIX 8: COUNTRY-SPECIFIC REQUIREMENTS ............................................................. 94 
10.9 APPENDIX 9: AB BREVIATIONS................................................................................................... 94 
10.10  APPENDIX 10: PROTOCOL AMENDMENT HISTORY ................................................................ 95 
10.11  APPENDIX 11: COPD ASSESSMENT TEST ............................................................................... 96 
10.12  APPENDIX 12: ST. GEORGE’S RESPI[INVESTIGATOR_310830] (SGRQ) ............................ 97 
10.13  APPENDIX 13: EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE TOOL (EXACT) ........................................................................................................... 103
 
10.14  APPENDIX 14: EUROQOL QU ESTIONNAIRE (EQ-5D-5L) ....................................................... 106 
10.15  APPENDIX 15: DEFINITI ON OF AN APHYLAX IS ....................................................................... 109 
10.16  APPENDIX 16: LIST OF OPPORTUNISTIC INFECTIONS......................................................... 110 
10.17  APPENDIX 17: FUTURE USE OF SA MPLES............................................................................. 111 
11 REFERENCES............................................................................................................................. 112 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: [ADDRESS_1225986] OF TABLES 
Table 1 - Objectiv es and endpoints............................................................................................. .................. 27 
Table 2 - Overview of Investigatio nal Medicinal Produc ts administered....................................................... 40 
Table 3 – Reliever Medication –Salbu tamol/Albuterol N ebulizer Solution.................................................... 42 
Table 4 - Reliever Medication - Levosalbutamol/Levalbuterol Nebulizer Solution........................................ 42 
Table 5 - Reliever Medication - Ipratropi[INVESTIGATOR_208405]/short-acting β agonists [SABA] Nebulizer 
Solutions...................................................................................................................... .................................. [ADDRESS_1225987] ........................................................... .60 
Table 7 – Adverse event reporting ................................................................................................................ 62 
Table 8 - Summary of handling procedur es for pharmacokinetic  (PK) samples........................................... 65 
Table 9 - Summary of bioanalytical me thods for pharmacokinetics samples ............................................... 65 
Table 10 - Summary of handling procedures  for antidrug antibod y (ADA) samples..................................... [ADDRESS_1225988] OF FIGURES 
Figure 1 - Graphical study design .............................................................................................. ................... 16 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 10 
 1 PROTOCOL SUMMARY 
1.1 SYNOPSIS 
Protocol title:  A randomized, double-blind, placebo- controlled, parallel-group, Proof-of-
Concept (PoC) study to assess the efficacy, safety and tolerability of SAR440340, 
in patients with moderate -to-severe chronic obstructive pulmonary disease 
(COPD) 
Short title:  Proof-of-Concept study to assess the efficacy, safety and tolerability of 
SAR440340 (anti-IL-33 mAb) in patients with modera te-to-severe chronic 
obstructive pulmonary disease (COPD) 
Rationale: 
Chronic obstructive pulmonary di sease (COPD) is a highly prevalent disease worldwide, 
associated with significant ec onomic burden, and for which available standard-of-care therapy 
shows insufficient treatment effect on symptoms , lung function, exacerbations and long term 
evolution of the disease. Interleukin-33 (IL-33) is a pro-inflammatory cytokine that initiates and 
amplifies innate and adaptive inflammatory cascades, in response to epi[INVESTIGATOR_877314], viruses, cigarette  smoke, and air pollutants. The 
objective of the current study is to investig ate the effects of 300 mg SAR440340 (a human 
monoclonal antibody that targets IL-33), adminis tered SC once every 2 weeks as compared to 
placebo on reducing the incidence of exacerbations  in patients with mode rate-to-severe COPD. 
Objectives and endpoints  
Objectives Endpoints 
Primary 
• To investigate effects of SAR440340 (anti-IL 33 mAb) 
compared with placebo, on the annualized rate of 
moderate-to-severe acute exacerbations of COPD 
(AECOPD) over up to 52 weeks of treatment. 
 
 - Annualized rate of moderate*-to-severe** AECOPD over the 
treatment period. 
 
- *Moderate exacerbations are recorded by [CONTACT_877356] (such as intramuscular, intravenous or 
oral) and/or antibiotics.  
- ** Severe exacerbations are recorded by [CONTACT_714376][INVESTIGATOR_059], emergency medical care visit or resulting in death. 
Key secondary 
• To investigate effects of SAR440340 compared with 
placebo, on improving respi[INVESTIGATOR_4806], as assessed by 
[CONTACT_877357]1 over 24 weeks. • Average change from baseline to Week 16-24*** in FEV1 
(pre-bronchodilator)  
 
*** Model-based averages across Weeks 16, 20 and 24 will be compared between the treatment groups 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 11 
 Overall design: 
Multinational, randomized, double-b lind, placebo controlled, parallel group (2 groups), Proof of 
Concept (PoC) study that is designed to assess the efficacy, safety, and tolerability of SAR440340 
in patients with moderate -to-severe COPD on an established Long-acting β2 adrenergic agonist 
(LABA), Long-acting muscarinic antagonist (L AMA), and/or ICS background therapy (double or 
triple therapy). Patients will be treated with SAR440340 or placebo for a minimum of 24 weeks 
and up to a maximum of 52 weeks*, a nd a 20-week safety follow-up period. 
* This study employs a variable treatment duration from 24 to 52 weeks to maximize data for the 
primary endpoint (annualized rate of exacerbation)  in a time-efficient manner. Patients enrolled 
in the trial will remain in the treatment period for up to a maximum of [ADDRESS_1225989] patient randomized completes a minimum treatment period of 24 weeks. Of note, the accrual and drop-out rates will be closely monitored. If the accrual rates are significantly lower than planned 
and/or the drop-out rates are higher than expecte d, the minimum treatment duration may be 
extended to achieve the desired amount of total exposure. The maximum treatment duration of 52 weeks will not be changed. 
The study duration is outlined below: 
• Screening period (10 days to 4 weeks)  
• Randomized investigational me dicinal product (IMP ) treatme nt period (24 to 52 weeks) 
• Post IMP safety follow-up treatment period (20 weeks). 
At screening, patients must be on standard of care background therapy, for 3 months prior to Visit 
2/Randomization and at a stable dos e for at least 1 month prior to the Screening Visit 1, including 
either: 
• Double therapy: LABA + LAMA or ICS + LABA or ICS + LAMA. 
OR 
• Triple therapy: ICS + LABA + LAMA. 
Patients who satisfy the inclusion and exclus ion criteria will be randomized (1:1) to:  
• SAR440340 (300 mg) administered as 2 SC injections every 2 weeks (q2w) for 24 to 52 
weeks  
• Matching placebo for SAR440340 administered as 2 SC injections q2w for 24 to 52 weeks  
It is planned to enroll approximately 50% of  patients on ICS-containing background therapy 
(ICS+LABA; ICS+LAMA or ICS +LABA+LAMA). 
Patients must be willing to stay on their established background medication for COPD throughout 
the duration of the study. 
Visits up to 52-week IMP treatment period will occur every other week and will be followed by a 
20-week observational follow-up period. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 12 
 Treatment discontinuation follow-up:  
Patients who withdraw from stud y treatment (prior to completing the planned duration of IMP 
treatment) will perform, as soon as possible, the early treatment discontinuation visit (ETD) with 
all assessments normally planned for the EOT visit, to assure a complete clinical assessment in 
close temporal proximity to the premature terminati on of study treatment is available. In addition, 
and to allow assessment of patient outcomes over the stipulated study period, patients will be asked and encouraged to complete all remaining study treatment visits, and participate in all safety follow-up assessments according to the visi t schedule with a +/-5 day window.  For such 
patients the assessment schedule will be reduced (See study flowchart for patients after permanent treatment discontinuation in Section  1.3.2) and alternate visits during the planned treatment period 
may be conducted by [CONTACT_648] (those with odd visit numbers, except for the planned EOT), as can visits F1 and F2.  
Under exceptional circumstances when a patient cannot come to the site for a scheduled visit, a 
phone contact [CONTACT_194276]. During the phone contact, at least information about AEs, 
concomitant medication a nd COPD exacerbation events should be collected. 
Post IMP treatment follow-up: 
Upon completing the 24-52 weeks randomized IM P treatment, patients w ill continue background 
therapy and enter the 20-week safety follow-up period.  
Number of participants: 
Approximately 340 patients will be  randomized in this study ( 170 patients per arm) of which 
approximately 50% of patie nts should present with a blood eosinophil count of ≥  250 /mm
3 and 
about 50% of patients with a blood eosinophil count of <250 /mm3. All randomized participants 
who receive at least 1 dose of IMP will be included in the efficacy and safety analysis. See 
Section  9.2 for sample size determination and Section  9.3 for analysis populations. 
Intervention groups and duration: 
Study participation for each patient will be up to a total of approximately [ADDRESS_1225990] IMP treatment period. 
Study intervention(s) 
Investigational medicinal products(s)
 
SAR440340  
• Formulation: Sterile SAR440340 w ill be provided in one [ADDRESS_1225991] (287 mg) is reconstituted 
with 2.5 mL of sterile water for injec tion resulting in 2.9 mL of 100 mg/mL SAR440340. 
A volume of 1.5 mL per injection will be wit hdrawn from the vial. Patients will receive 2 
injections per dose 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 13 
 • Route(s) of administration: Subcutaneous injection (sites should alternate between the 
upper thighs, 4 quadrants of the abdomen or the upper arms, so that the same site is not 
injected twice during consecutive visits) 
• Dose regimen: 2 SC injections q2w for 24-52 weeks. 
Matching placebo for SAR440340  
• Formulation: Sterile placebo will be provided in one 20 mL vial containing lyophilisate 
placebo. One vial of lyophilisate is reconstitute d with 2.5 mL of sterile water for injection 
resulting in 2.9 mL IMP. A volume of 1.5 mL per injection will be withdrawn from the 
vial. Patients will receive 2 injections per dose 
• Route(s) of administration: Subcutaneous injection (sites should alternate between the 
upper thighs, 4 quadrants of the abdomen or the upper arms, so that the same site is not 
injected twice during consecutive visits) 
• Dose regimen: 2 SC injections q2w for 24-52 weeks. 
Noninvestigational medicinal products(s)  
Background therapy  
Patients should continue their established standard of care background therapy for COPD 
throughout the study (double therapy [LABA + LAMA or ICS + LABA or ICS + LAMA] or triple therapy [ICS + LABA + LAMA]). 
• Formulation: Dry powder inhaler (DPI), metere d dose inhaler (MDI) or pocket nebulizer  
• Route(s) of administration: Oral inhalation 
• Dose regimen: As prescribed 
Patients must be willing to stay on their established background medication for COPD throughout the duration of the study. After successful management of an acute exacerbation of COPD (e.g. with oral corticosteroids and/or  antibiotics), all efforts should be made to resume the initial 
background COPD treatment regimen if in the inves tigator’s opi[INVESTIGATOR_877315]. 
After 1 severe or 2 moderate exacerbations of COPD, dose adjustments in background therapy 
will be permitted for symptom c ontrol and as needed for the remainder of the trial period. 
Reliever Medication
 
Patients may use albuterol/salbutamol or levalbuterol/levosalbutamol (including ipratropi[INVESTIGATOR_208411]/short-acting β agonists [SABA] combinations) as  reliever medication as needed 
during the study. Nebulizer solutions may be  used as an alternative delivery method. 
• Formulation: Dry powder inhaler (DPI), metere d dose inhaler (MDI) or pocket nebulizer  
• Route(s) of administration: Oral inhalation 
Dose regimen: As prescribed. 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 14 
 Statistical considerations:  
• Primary efficacy analysis: 
For the primary efficacy endpoint the annua lized exacerbation rate, a negative binomial 
regression model will be used to assess treatment differences. The model will include the 
total number of events occurring during the treatment period (up to Week 52) as response variable, and the treatment group, the baseline eosinophil strata and region (pooled countries) as covariates. Log-transformed obser vation duration will be the offset variable. 
Parameters will be estimated using the maximum lik elihood method with the Newton-
Raphson algorithm.  
Comparison of the annualized event rates between the treatment group and the placebo 
group will be made within th is model and the rate ratio s and their 95% confidence 
intervals will be estimated.  In the case of premature discontinuation of study drug, a secondary analysis will include 
events up to [ADDRESS_1225992] dose. 
Using the same method, subgroup analyses will be performed separately by [CONTACT_877358] ( ≥250 /mm3 versus <250 /mm3). 
• Analysis of secondary endpoints: 
Key secondary endpoint  
The key secondary efficacy endpoint the average change from baseline to Week 16- [ADDRESS_1225993] model with repeated measures (MMRM) approach. Model-based averages across Weeks 16, 20 and 24 will be 
compared between the treatment groups. The dependent variable is the change from baseline in pre-bronchodilator FEV1 at each time points. The model will include baseline 
FEV1 value, treatment group, visit, and tr eatment-by-visit inte raction, the baseline 
eosinophil strata, and region (pooled countries), as covariates. An unstructured correlation 
matrix will be used to model the within-patient correlations. Parameters will be estimated using restricted maximum likelihood met hod with the Newton-Raphson algorithm. 
Additional covariates such as the background medications, age, height, gender, race and 
smoking status will be considered for inclusion in the analysis model based on evaluation of blinded data and the final analysis model documented in the statistical analysis plan 
(SAP). 
Comparison between the treatment group and th e placebo group will be made within this 
model and the least square mean difference and their 95% confidence intervals will be 
estimated. 
In the case of premature discontinuation of study drug the primary analysis will include 
data up to [ADDRESS_1225994] dose. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104-SAR440340 11-Jun-2018 Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 15 
 Subgroup analyses will be performed using th e same method by [CONTACT_877359] 
(≥250 /mm3 versus <250 /mm3). 
Other secondary efficacy endpoints:  
Change from baseline to Week [ADDRESS_1225995] Week 24 in FEV1 (both pre-bronc hodilator and post-bronchodilator).    
Time to first moderate or severe AECOPD will be analyzed using a Cox regression model 
with treatment, baseline eosinophil strata, and region (pooled country) as covariates. The Kaplan-Meier (K-M) method will be used to estimate the probabilities of first AECOPD at 
specific time points for each group. Additional covariates will be considered based on evaluation of blinded data and the final analysis model documented in the SAP. 
• Safety analysis 
Safety analyses will be desc riptive, based on the safety population. The safety analysis 
will focus on the treatment-emergent adverse ev ent (TEAE) period. This period is defined 
as the time from the first administration of the IMP to [ADDRESS_1225996] 
administration of the IMP. During the stud y, unblinded data will be reviewed on an 
ongoing basis for safety and efficacy by a Data Monitoring Committee (DMC). 
Data Monitoring Committee: Yes 
An internal DMC will be comprise d of individuals with expertis e in the diseases under study, 
biostatistics, or clinical research. The DMC memb ers are independent of the project/study teams 
and are not involved in the study conduct. The pr imary responsibilities of the DMC are to review 
and evaluate the study data during the course of  the trial and make a ppropriate recommendations 
regarding the conduct of the clinical trial to project/study team.    
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1225997] p atient completing 
planned treatment (EOT visit), whichever occurs earlier, whichever occurs earlier Section  4.1.  
2 End of Treatment (EOT) visit to occur [ADDRESS_1225998] administration of IMP.
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 17 1.3 SCHEDULE OF ACTIVITIES (SOA)  
The Schedule of Activities (SoA) for patients who complete the planned treatment is described in Section  1.3.1. Patients who withdraw treatment 
must complete the Early Treatment Discontinuation (ETD) visit and follow the assessment in Section  1.3.2  for the remaining visits.   
1.3.1 Schedule of Activities (SoA) for Patients who complete the Planned Treatment  
 
 S R/
B                              
VISIT [ADDRESS_1225999] X-raye X                                
I n c l u s i o n / e x c l u s i o n  X  X                               
COPD Assessment Test 
(CAT)f X  X                               
Smoking status X X X X X X X X  X  X  X  X  X  X  X  X  X X X X X X 
Prior & concomitant 
medications X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Study treatment 
administration                                 
Call IVRS/IWRS  X X X X X X X X X X X X X X X X X X X X X X X X X X X X   X 
R a n d o m i z a t i o n   X                               
IMP administrationg  X X X X X X X X X X X X X X X X X X X X X X X X X X     
Dispense or upload 
electronic diaryh X X X X X X X X X X X X X X X X X X X X X X X X X X X X X  X 
Safety                                 
Physical examinationi X  X       X       X       X         X    X 
Vital signsj X X X X X X X  X X X X X X X X X X X X X X X X X X X X  X X  X 
Electrocardiogram  (12 lead)
k X X      X       X       X         X    X  
Hematology, biochemistry, 
urinalysis including X  X     X    X     X       X        X    X  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 18  S R/
B                              
VISIT 1 2a,
b 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 EOT 
c F1 F2d EOS 
WEEK W-4  
to  
W-1 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52  60 66 72 
cotininel 
Hepatitis and HIV 
Serology testsm X                                
Q u a n t i f e r o n  G o l d   X                                
Pregnancy ( β-HCG blood) 
testn X                                
Urine pregnancy testn  X  X  X  X  X  X  X  X  X  X  X  X  X  X   X 
Adverse event reporting, 
including SAEs X X X X X X X  X X X X X X X X X X X X X X X X X X X X  X X X X 
Pharmacokinetics                                 
Serum samples for SAR440340 
concentrationo  X  X  X   X  X   X     X       X         X  X   X  
Anti-SAR440340 
antibodyp  X      X       X               X    X  
Biomarkers                                 
Blood eosinophils and 
neutrophils X X  X
q  X X
q      X       X         X  Xq  X 
Total IL33 and sST2o X  X   X   X  X       X               X  X   X  
C a l c i t o n i n  X  X   X   X  X       X               X  X   X  
P A R C  X  X   X     X       X       X         X     
E o t a x i n - 3  X  X   X     X       X       X         X     
T o t a l  I g E  X  X   X     X       X               X     
F i b r i n o g e n  X  X             X               X     
FeNO pre-bronchodilator 
(optional)r  X   X   X  X       X       X             
FeNO post-bronchodilator 
(optional) r  X   X   X  X       X       X             
Induced sputum (optional)s  X             X               X     
                                
Blood samples for RNA 
sample (optional) X  X   X           X               X     
Blood sample archival for 
exploratory research 
(optional)t X  X   X     X       X       X         X     
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 19  S R/
B                              
VISIT 1 2a,
b 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 EOT 
c F1 F2d EOS 
WEEK W-4  
to  
W-1 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52  60 66 72 
DNA Pharmacogenomics 
analysis (optional)  X                               
Efficacy                                 
COPD exacerbation reporting by [CONTACT_737]   X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Spi[INVESTIGATOR_038] (pre-BD)u, v X X X X  X  X  X  X  X  X  X  X  X  X  X X X X  X 
Spi[INVESTIGATOR_038] (post-BD) u, v X X X X  X  X      X       X         X  X   X 
EXACTw Every day (diary) from screening to week 52    
SGRQw  X   X   X  X       X       X         X  X   X  
EQ-5D-5Lw  X            X               X  X   X  
Actigraphy  
Optional assessments (US/Canada only) Co
n-
tin
uos      Con-
tinuos     Con-
tinuos                  
At-home spi[INVESTIGATOR_038] (FEV1) Optional assessments (US/Canada only) 
BI
D      B I D      B I D                   
S= Screening; R/B= Randomization/Baseline; F=Follow-up 
β-hCG = Human chorionic gonadotropin-beta; BID = twice daily assessments; CAT = COPD Assessment Test; continuous = subsequent vi sits during the treatment period; COPD = chronic obstructive pulmonary 
disease; cont. = continuous; DNA = Deoxyribonucleic acid ; EDTA = Ethylenediaminetetraacetic acid ; EOS = End of Study; EOT = End of treatment; EQ-5D= Euro Quality of Life-5 Dimension questionnaire; EXACT = Exacerbations of COPD tool (EXACT); HIV = human immunodeficiency virus; IgE = Immunoglobulin E; IMP = Investigational Medical Product; IVRS = Interactive Voice Response System; IWRS = Interactive Web Response System; LABA = Long-acting β2 adrenergic agonist; LAMA = Long-acting muscarinic antagonist ;PARC = Pulmonary and activation-regulated chemokine; PK = Pharmacokinetic; RNA = Ribonucleic acid; 
SABA = Short-acting beta-agonists; SAEs = Seri ous adverse events; SC = s ubcutaneous; SGRQ = St. George 's Respi[INVESTIGATOR_6015]. 
a Randomization/baseline Visit is defined as Day 1. The visit schedule should be adhered to within ±3 days for the screening peri od and randomized IMP treatment period, and ±[ADDRESS_1226000] 
IMP treatment period. 
b All assessments at Visit 2 (Day 1) are to be conducted pre-IMP dose with the exception of the assessment of local tolerability of SC injections. 
c End-of-treatment visit: See Section  4.[ADDRESS_1226001] X-ray to be performed unless a <[ADDRESS_1226002] x-ray/chest CT/chest MRI is available. In case chest-X-ray is not feasi ble due to local regulations, magnetic reso nance imaging (MRI) w ill be perfor med.  
f The 
COPD Assessment Test  (CAT) is to be registered through the patient’s electronic diary. 
g IMP (SAR440340 or placebo) to be administered every [ADDRESS_1226003] 30 minutes after a dministration of all IMP injections.  Monitoring period may be extended as per country 
specific requirements.  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 20 h Electronic diary is used for recording of patient’s answers to the EXACT, SGRQ and EQ -5D-5L questionnaires, CAT assessment as w ell as for recording reliever medication. This device is dispensed at Screening 
Visit 1 (including instructions for use) and recorded information is downloaded from this device on the other indicated days. A t EOS visit the electronic diary is downloaded and returned to the site.  
i Complete physical examinations will include skin, nasal ca vities, eyes, ears, respi[INVESTIGATOR_696], cardiovascular, gastrointestinal, ne urological, lymphatic, an d musculoskele tal systems. 
j Vital signs, including systol ic and diastolic blood pressure (mmHg), pulse rate (beats per minute), body temperature (°C), and respi[INVESTIGATOR_877316], baseline and every subsequent on-site 
visit. Height (cm) will be measured at screeni ng (Visit 1) only. Body weight (kg) w ill be measured at screening (Visit 1) and a t EOT/EOS visits. 
k ECG to be centrally collected & read.  
l Hematology will include hemoglobin, hematocrit, pl atelet count, total white blood cell count with 5-part differential count, an d total red blood cell count. Serum chemistry will include creatinine, blood urea nitrogen, 
glucose, lactate dehydrogenas e, uric acid, total cholesterol,  total protein, albumin, total b ilirubin, alanine aminotransferase , aspartate aminotransferase, alkaline phosphatase, electrolytes (sodium, potassium, 
chloride), bicarbonate, and creati ne phosphokinase. Ur inalysis will include specific gravity,  pH, glucose, ke tones, blood, prot ein, nitrate, leukocyte es terase, urobilinogen a nd bilirubin. If any parameter on the 
dipstick is abnormal, a urine sample should be sent to the central laboratory for quantitative measurement. If positive for pro tein and/or red blood cells, microscopic analysis will be performed by [CONTACT_11378]. Cotinine w ill be tested using the urine sample collected. 
m Clinical laboratory testing at Screeni ng Visit 1 will include hepatitis screen covering hepatitis B surface antigen (HBs Ag), h epatitis B surface antibody (HBs Ab), hepatitis B core antibody (HBc Ab), hepatitis C virus 
antibodies (HCV Ab), Human Immunodeficiency Virus (HIV) screen (Anti-HIV-1 and HIV-2 antibodies) and anti-nuclear antibody (ANA ). In case of results showing HBs Ag (negative), and HBc Ab (positive), an 
HBV DNA testing may be performed prior to randomization to rule out a false positivity if the Investigator believes the patient  is a false positive, or to clarify the serological status if the Investigator finds it unclear to 
interpret in absence of known HBV infection. In case of results showing HCV Ab (positive), an HCV RNA testing may be performed to rule out a false positivity, if the Investigator believes the patient is a false 
positive. Note: Anti-ds DNA antibody will be tested if ANA is positive ( ≥1:160 titer).  
n Only for women of childbearing potential: serum pregnancy test at Screening/V1 and urine pregnancy tests at every [ADDRESS_1226004] to confirm the pregnancy should be performed as soon as possible. Pregnancy 
will lead to definitive treatment discontinuation in all cases. 
o Refer to central lab manual for collection details. 
p If ADA assessment at week 12 is positive, additional measurements may be performed from PK samples collected at Week 4. 
q The complete hematology panel will be performed.  
r FeNO: meas ur 
ement at sites only with access to FeNO equipment. 
s Optional sputum sample at V2 should be collected post-randomization and prior to dosing with IMP, as long as patient consents to the optional collection.  Only available at select sites in some countries.  
t Archived samples may be used for research purposes related to COPD or other respi[INVESTIGATOR_877317] (eg, exploratory biomarkers of disease or drug effect), pathway 
biology, additional drug safety assessments or development and validation of bioassay methods beyond those defined in the present protocol.   
u Spi[INVESTIGATOR_877318] (ERS)/Amer ican Thoracic Societ y (ATS) [ADDRESS_1226005] dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at least [ADDRESS_1226006] 12 hours (ultra -long acting LABA like vilanter ol should be withheld for at least 24 hours) and withholding the last dose of LAMA for at 
least 24 hours. This will be verified before  performing the measurements. Note: When both pre and post-bronchodilator spi[INVESTIGATOR_23943] y is assessed, the post-bronchodilator spi[INVESTIGATOR_208415] (i e, 30 minutes for albuterol or other SABA). 
v Following randomization and during the treatment period - if spi[INVESTIGATOR_877319]. 
w The EXACT, SGRQ and EQ-5D-5L are to be completed in the patient’s electronic diary.  
 
  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 21 1.3.2 Schedule of Activities (SoA) for Patients After Early Treatment Discontinuation  
 
 ETD
a                              
VISIT   
3
b
 4 5
b 6 7
b 8 9
b 10 11
b 12 13
b 14 15
b 16 17
b 18 19
b 20 21
b 22 23
b 24 25
b 26 27
b EOT 
c F1 
b F2
b EOS 
WEEK  2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52  60 66 72 
Smoking status X X X X X X X  X  X  X  X  X  X  X  X  X X X X X X 
Prior & concomitant 
medications X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
C a l l  I V R S / I W R S  X                           X    X 
Upload electronic diaryd Every on-site visit up to 12 weeks after ETD 
Safety                                
Physical examinatione X       X       X       X         X    X  
Vital signsf X       X       X       X         X    X  
Electrocardiogram  
(12 lead)g  X      X      X      X        X   X 
Hematology, biochemistry, 
urinalysis including 
cotinineh X     X    X     X       X         X    X  
Urine pregnancy testi X  X  X  X  X  X  X  X  X  X  X  X  X  X   X 
Adverse event reporting, 
including SAEs X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Pharmacokinetics                                
Serum samples for SAR440340 
concentrationj X      X      X              X   X 
Anti-SAR440340 
antibodyk X       X       X               X    X 
Biomarkers                                
Blood eosinophils and 
neutrophils X    X    X     X       X         X    X  
Total IL33 and sST2j X                               
C a l c i t o n i n  X                               
P A R C  X                               
E o t a x i n - 3  X                               
Total IgE X                              
Fibrinogen X                              
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 22  ETD
a                              
VISIT   
3
b
 4 5
b 6 7
b 8 9
b 10 11
b 12 13
b 14 15
b 16 17
b 18 19
b 20 21
b 22 23
b 24 25
b 26 27
b EOT 
c F1 
b F2
b EOS 
WEEK  2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52  60 66 72 
Induced sputum (optional)  
m X                              
Blood samples for RNA 
sample (optional) X                              
Blood sample archival for exploratory research 
(optional)n X                               
Efficacy                                
COPD exacerbation 
reporting by [CONTACT_3786] X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Spi[INVESTIGATOR_038] (pre-BD)o, p X   X   X  X       X       X         X    X  
Spi[INVESTIGATOR_038] (post-BD) o, p X   X   X  X       X       X         X    X  
EXACTq  Every day (diary) up to 12 weeks after ETD 
SGRQq X                               
EQ-5D-5Lq X                               
Actigraphy  
Optional assessments 
(US/Canada only)  X                              
 
At-home spi[INVESTIGATOR_038] (FEV1) 
Optional assessments 
(US/Canada only)
 X                              
 
F=Follow-up 
β-hCG = Human chorionic gonadotropin-beta; BID = twice daily assessments; CAT = COPD Assessment Test; continuous = subsequent vi sits during the treatment period; COPD = chronic obstructive pulmonary 
disease; cont. = continuous; DNA = Deoxyribonucleic acid ; EDTA = Ethylenediaminetetraacetic acid ; EOS = End of Study; EOT = End of treatment; EQ-5D= Euro Quality of Life-5 Dimension questionnaire; EXACT = Exacerbations of COPD tool (EXACT); HIV = human immunodeficiency virus; IgE = Immunoglobulin E; IMP = Investigational Medical Product; IVRS = Interactive Voice Response System; IWRS = Interactive Web Response System; LABA = Long-acting β2 adrenergic agonist; LAMA = Long-acting muscarinic antagonist; PARC = Pulmonary and activation-regulated chemokine; PK = Pharm acokinetic; RNA = Ribonucleic acid; 
SABA = Short-acting beta-agonists; SAEs = Seri ous adverse events; SC = s ubcutaneous; SGRQ = St. George 's Respi[INVESTIGATOR_6015]. 
a Patients who withdraw from study treatment (prior to completing the planned duration of IMP treatment) will perform, as soon as  possible, the early treatment discontinuation visit (ETD) visit. Once the ETD is 
performed, patients should follow the ETD SoA based on their original visit number, and the visit schedule should be adhered to  within ±5 days. 
b Visit may be performed by a phone call. 
c End-of-treatment visit. For patients who discontinue treatment, this visit corresponds to the planned EOT visit. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 23 d Electronic Diary will be used on daily basis for period of 12 weeks after ETD. The CAT assessment, and reliever medication will  not be collected in patients after early treatment discontinuation. 
e Complete physical examinations will include skin, nasal ca vities, eyes, ears, respi[INVESTIGATOR_696], cardiovascular, gastrointestinal, ne urological, lymphatic, an d musculoskele tal systems. 
f Vital signs, including systol ic and diastolic blood pressure (mmHg), pulse rate (beats per minute), body temperature (°C), and respi[INVESTIGATOR_877320]-site visits. Body weight (kg) will be measured at 
EOT/EOS visits. 
g ECG to be centrally collected & read.  
h Hematology will include hemoglobin, hematocrit, pl atelet count, total white blood cell count with 5-part differential count, an d total red blood cell count. Serum chemistry will include creatinine, blood urea nitrogen, 
glucose, lactate dehydrogenas e, uric acid, total cholesterol,  total protein, albumin, total b ilirubin, alanine aminotransferase , aspartate aminotransferase, alkaline phosphatase, electrolytes (sodium, potassium, 
chloride), bicarbonate, and creatinine phosphoki nase. Urinalysis will include specific gravity, pH, gl ucose, ketones, blood, pr otein, nitrate, leukocyte esterase, urobilinogen and bilirubin. If any parameter on the 
dipstick is abnormal, a urine sample should be sent to the central laboratory for quantitative measurement. If positive for pro tein and/or red blood cells, microscopic analysis will be performed by [CONTACT_11378]. Cotinine w ill be tested using the urine sample collected. 
i Only for women of childbearing potential: urine pregnancy test at ETD and every [ADDRESS_1226007] 
to confirm the pregnancy should be performed as soon as possible. 
j Refer to central lab manual for collection details. 
k If ADA assessment at week 12 is positive, additional measurements may be performed from PK samples from Week 4. 
l FeNO: measurement at sites only with access to FeNO equipment. 
m Optional sputum sample at ETD should be collected post-randomization and prior to dosing with IMP, as long as patient consents to the optional collection.  Only available at select sites in some countries.  
n Archived samples may be used for research purposes related to COPD or other respi[INVESTIGATOR_877317] (eg, exploratory biomarkers of disease or drug effect), pathway 
biology, additional drug safety assessments or development and validation of bioassay methods beyond those defined in the present protocol.   
o Spi[INVESTIGATOR_877318] (ERS)/Amer ican Thoracic Societ y (ATS) [ADDRESS_1226008] dose of salbutamol/albuterol or levosalbutamol/levalbuterol for at least [ADDRESS_1226009] 12 hours (ultra -long acting LABA like vilanter ol should be withheld for at least 24 hours) and withholding the last dose of LAMA for at 
least 24 hours. This will be verified before  performing the measurements. Note: When both pre and post-bronchodilator spi[INVESTIGATOR_23943] y is assessed, the post-bronchodilator spi[INVESTIGATOR_208415] (i e, 30 minutes for albuterol or other SABA). 
p Following randomization and during the treatment period - if spi[INVESTIGATOR_877321]. 
q The EXACT, SGRQ and EQ-5D-5L are to be completed in the patient’s electronic diary.
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 24 2 INTRODUCTION 
SAR440340 (also known as REGN3500 or R3500) is a human monoclonal antibody (mAb) that 
targets IL-33 and is under development as a poten tial novel treatment for bo th asthma and COPD. 
2.1 STUDY RATIONALE 
Chronic obstructive pulmonary dis ease (COPD) is a highly prevalent disease worldwide that is 
associated with significant ec onomic burden and for which availa ble standard-of-care therapy 
shows insufficient efficacy on symptoms, lung fu nction, exacerbations and long-term evolution of 
the disease. IL-33 is a pro-inflammatory cytokine that initiates and amplifies innate and adaptive 
inflammatory cascades in response to epi[INVESTIGATOR_877322], viruses, cigarette smoke, and air pollutants. The objective of the current study is to investigate the effects of 300 mg SAR440340 administered SC once every 2 weeks as compared to placebo on reducing the incidence of exacerbati ons in patients with mode rate-to-severe COPD.  
2.2 BACKGROUND 
2.2.1 Chronic obstructive pulmonary disease  
Chronic obstructive pulmonary dis ease (COPD) is a heterogeneous syndrome associated with an 
abnormal inflammatory immune response of the lung to noxious partic les and gases ( 1). Chronic 
inflammation causes structural changes, narrowing of the small airways, and destruction of the 
lung parenchyma that leads to the loss of alveolar attachments to the small airways and decreases 
lung elastic recoil. It results in progressive airflow obstruction that is only partly reversible or even irreversible. The inflammation component of  COPD is thought to involve many cell types 
including structural cells, T lymphocytes, neutro phils, macrophages, and their biological products. 
In some patients, there may also be an increase  of eosinophils, T-helper (Th) [ADDRESS_1226010] common respi[INVESTIGATOR_877323], cough and/or sputum production. The dis ease is further aggravated by [CONTACT_877360], 
particularly for severe COPD. These are most ofte n due to viral and bacter ial infections of the 
lungs which trigger the inflammatory response,  tissue destruction, and the resultant hypoxia. 
Exacerbations in COPD patients are associated with rapid disease progression (rate of lung function decline over time) and increased risk of mortality. Medical comorbidities such as cardiovascular disease, diabet es, lung cancer, skeletal mu scle dysfunction, osteoporosis, 
psychological disturbances, and metabolic syndrome are co mmon among COPD patients and 
occur across the spectrum of disease severity.  
Chronic obstructive pulmonary disease is a highly prevalent, serious and progressive disease 
resulting in significant morbidity,  mortality, and economic burden ( 2, 3). In the US alone there are 
more than 12 million diagnosed patients and the incidence of COPD is expected to grow rapi[INVESTIGATOR_877324]. COPD is a progressive a nd irreversible inflammatory lung disease that 
is periodically punctuated by [CONTACT_877361] 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226011] of care for moderate COPD star ts with bronchodilators (such as long-acting 
muscarinic antagonists [LAMA] or long-acting β2 agonists [LABA]), and as disease progresses 
bronchodilators are combined with other drugs such as inhaled corticosteroids (ICS), and 
phosphodiesterase type 4 (PDE-4 ) inhibitors (roflumilast) ( 4, 5, 6). The major limitations of the 
existing agents for COPD include modest efficacy and risk of respi[INVESTIGATOR_18073] (ICS). Oral or 
systemic corticosteroids are reserved for treatment of exacerbations given their unacceptable long-
term safety profile in the COPD  population. No approved therapeutic agent blocks the decline in 
forced expi[INVESTIGATOR_3741] 1 second (FEV1) over time or modifies the progressive disease course of COPD. Thus there is a high unmet need  for more effective treatment of this disease. 
Currently, no targeted biological treatments addressing the immunological underpi[INVESTIGATOR_208425]. The anti-interleukin (IL)-[ADDRESS_1226012] 18%-20% 
reduction of exacerbations in CO PD patients with high blood eosinophils. The anti-IL-[ADDRESS_1226013] that the FEV1 improvement versus pla cebo averaging approximately 150 mL over time is 
mainly driven by [CONTACT_877362]. In this study, no reduction of exacerbations was seen in the per-protocol pop ulation, and a numerical, but not statistically 
significant, reduction of exacerbation was seen in the subgroup of patients with high blood 
eosinophils ( 7, 8).  
Thus, significant unmet medical needs continue to exist in the growing population of patients with 
COPD. The main objective for new treatments is to further improve COPD symptoms, lung function, and prevent exacerbations, while optimizing adherence to the treatment. 
2.2.2 SAR440340 - Anti-IL-33 monoclonal antibody 
SAR440340 is a human mAb that targets IL-33. IL-33 is a proinflammatory cy tokine that initiates 
and amplifies innate and adaptive inflammatory cascades ( 9) in response to epi[INVESTIGATOR_877325] (“alarmin”) due to exposure to airborne  allergens, viruses, cigarette smoke, and air 
pollutants. Accumulating evidence from human studies  and animal models suggests that IL-[ADDRESS_1226014] been reported  in bronchial cells of COPD 
patients ( 10, 11). It is also known that IL-33 protein ex pression in the lungs correlates with COPD 
severity and is a negatively correlated with FEV1 ( 11). A separate study has found that plasma IL-
33 level in patients with stable  COPD was related to eosinophil count and chronic bronchitis 
phenotype ( 12). Supporting data from a preclinical muri ne smoking model of COPD suggests a 
dual role for IL-33 in amplifying lung inflamma tion during viral exacerbations of COPD. Initially, 
smoke inhalation upregulates intrac ellular IL-33 in mice, as well as the proportion of epi[INVESTIGATOR_877326]-33; secondly, viral infection leads to focal cellular necrosis, release of IL-33, 
and increased production of proinf lammatory cytokines such as IL-6 and tumor necrosis factor- α 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 26 (TNF- α) in the lung ( 11). Therefore, it is hypothesized that blockade of IL-[ADDRESS_1226015] in the setting of environmental triggers such as infection or toxic inhalants 
may be a novel therapeutic approach to prevent exacerbations. 
2.3 BENEFIT/RISK ASSESSMENT 
The Phase 1 study in healthy subjects suggests that SAR440340 is well-tolerated at doses up to 10 
mg/kg administered IV as single dose. Unblinded safety data from the ongoing multiple ascending dose study (R3500-AS-1619, data as of February 23, 2018) in as thma patients have 
demonstrated that weekly doses of [ADDRESS_1226016] been reported in any of the Phase 1 studies. SAR440340 is expected to inhibit the 
proinflammatory activity of IL- 33, which is elevated in COPD patients. Thus, the benefit/risk 
profile for SAR440340 in this study supports its ev aluation as a potential agent for treatment of 
COPD. 
There is a potential risk of infection associated  with blocking of host defense pathways by 
[CONTACT_13108]440340. The preliminary safety data from the first in human (FIH) study of SAR440340 have 
revealed no safety signals. Therefore, the an ticipated safety of SAR440340 is considered 
reasonable, with close monitoring of adverse ev ents (AEs) and laboratory results throughout the 
study and follow-up period. The safety data and ot her potential risks (systemic hypersensitivity, 
embryo-foetal toxicity, immunogenicity) for SAR440340 are summarized in the Investigator's 
Brochure (IB). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 27 3 OBJECTIVES AND ENDPOINTS 
Table 1 - Objectives and endpoints 
Objectives Endpoints 
Primary 
• To investigate effects of SAR440340 (anti-IL 33 mAb) 
compared with placebo, on the annualized rate of 
moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment. 
 
 - Annualized rate of moderate*-to-severe** AECOPD over the 
treatment period.  
*Moderate exacerbations are recorded by [CONTACT_877356] (such as intramuscular, intravenous or oral) 
and/or antibiotics.  
** Severe exacerbations are recorded by [CONTACT_877363][INVESTIGATOR_059], 
emergency medical care visit or resulting in death. 
Secondary 
• To investigate effects of SAR440340 compared with 
placebo, on improving respi[INVESTIGATOR_4806], as assessed 
by [CONTACT_877357]1 over 24 weeks. • Average change from baseline to Week 16-24*** in FEV1 
(pre-bronchodilator)  
 
*** Model-based averages across Weeks 16, 20 and 24 
will be compared between the treatment groups 
• To evaluate effects of SAR440340  compared with placebo, 
on  Post-bronchodilator FEV1 over 24 weeks 
 • Change from baseline to Week 24 in FEV1 (post-
bronchodilator****)  **** Post-bronchodilator means 30 minutes after either 400 
mcg of salbutamol/albuterol (4 puffs of 100 mcg each) or 
80 mcg of ipratropi[INVESTIGATOR_1893] (4 puffs of 20 mcg each). 
• To evaluate effects of SAR440340  compared with placebo, 
on duration from baseline to first moderate or severe 
AECOPD event over up to 52 weeks • Time to first moderate or severe AECOPD. 
• To evaluate effects of SAR440340 compared with placebo, 
on safety and tolerability • Treatment-emergent adverse events (TEAE)  
• Serious adverse events (SAE) 
• Tertiary/exploratory   
• To evaluate the effects of SAR440340 compared with 
placebo, on patient reported symptoms and quality of life as documented by e-Diary and utilizing Exacerbations of 
Chronic Obstructive Pulmonary Disease Tool (EXACT), 
St. George’s Respi[INVESTIGATOR_6015] (SGRQ) and Euroqol-5Dimension (EQ 5D) questionnaire 
- in all patients treated with SAR440340/placebo 
- in subpopulations with high blood eosinophil level (≥250 /mm
3) and low blood eosinophil level (<250 
/mm3) • Change from baseline in the EXACT scores at Week 24 
• Change from baseline in the SGRQ scores at Week 24 
• Change from baseline in the EQ-5D scores at Week 24 
• To evaluate the pharmacokinetic (PK) profile of SAR440340 
in serum • Serum functional SAR440340 concentrations 
• To evaluate the effects of SAR440340 Antidrug antibodies 
(ADA ) • Antidrug antibodies (ADA) against SAR440340 
• To evaluate the effects of SAR440340 compared with 
placebo, on FEV1, AECOPD, and other relevant endpoints 
-  in subpopulations with high blood eosinophil level (≥250 /mm3) and low blood eosinophil level (<250 
/mm3) 
- in subpopulations according to use/no use of ICS • Change from baseline to Week 24 in FEV1 (pre-
bronchodilator and post-bronchodilator) 
• Rate of moderate-to-severe AECOPD  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 28 Objectives Endpoints 
with bronchodilators as background therapy, 
fibrinogen levels, and smoking status. 
• To evaluate the effects of pharmacogenomics on 
SAR440340  • Future Assessment of DNA or RNA samples for the 
pharmacogenomics sub study to identify genomic associations with clinical or biomarker response, other 
clinical outcome measures and possible AEs 
• To evaluate the effects of SAR440340 compared with 
placebo on other respi[INVESTIGATOR_185212] (expanded AECOPD endpoint) 
 • Change from baseline to Week 16-24 in FVC (% predicted 
and absolute values in mL). 
• Time to the first moderate and se vere exacerbations or time 
to study drug discontinuation (after Week 4) due to lack of 
efficacy, based on the investigator’s judgement (expanded 
AECOPD endpoint) 
• To evaluate the clinical symptoms of COPD in patients 
treated with SAR440340 versus placebo - in all patients treated with SAR440340/placebo 
- in subpopulations with high blood eosinophil level (≥250 /mm
3) and low blood eosinophil level (<250 
/mm3) 
- in subpopulations according to use/no use of ICS with bronchodilators as background therapy, fibrinogen levels, and smoking status • Time to first Clinically Important Deterioration (CID) as 
defined by [CONTACT_57939] >100 mL from baseline in trough FEV1 and /or deterioration in SGRQ by 4 units and/or 
moderate-to-severe AECOPD up to Week 24 (and over 
the 52 week variable treatment period 
• To evaluate the pharmacodynamics effects of SAR440340  • Blood eosinophil and neutrophil counts. 
• Levels of biomarkers of the interleukin (IL)-33 and/or Type [ADDRESS_1226017] 
- Total IL-33, sST2 levels 
- Calcitonin levels 
- PARC levels 
- Eotaxin-3 levels 
- Total IgE levels 
- Fibrinogen levels 
• Induced sputum for RNA expression (optional for patients at 
a subset of sites). 
• Optional: Messenger ribonucleic acid sequencing or whole 
transcriptome analysis. 
• Optional: DNA/RNA sample will be collected for 
pharmacogenomic effects. 
• Optional actigraphy (sl eep and activity) and home 
spi[INVESTIGATOR_038] (available for patients in US and Canada only):  
To evaluate the effects of SAR440340 compared to placebo on parameters of sleep, activity, and at-home 
spi[INVESTIGATOR_038]. 
 •
 Change from average measurement over baseline (2 weeks 
prior to randomization) to average measurements over 
Weeks 10-12 (2 weeks prior to Visit 8) and Weeks 22-24 
(2 weeks prior to Visit 14) of sleep and activity parameters.  
- Sleep: Total sleep time, wake after sleep onset, 
overnight activity counts - Activity: Daytime activity counts, percent of time spent in 
sedentary activity, percent of time spent in moderate to 
vigorous physical activity - Spi[INVESTIGATOR_038]: FEV1 
• Optional actigraphy (sl eep and activity) and home 
spi[INVESTIGATOR_038] (available for patients in US and Canada only):  
To compare the utility of at-home spi[INVESTIGATOR_877327]-clinic spi[INVESTIGATOR_038] • FEV1 (Spi[INVESTIGATOR_877328])  
• FEV1 (Spi[INVESTIGATOR_877329]) 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226018] for the evaluation of therapy in 
patients with COPD. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 30 4 STUDY DESIGN 
4.1 OVERALL DESIGN 
Multinational, randomized, double-b lind, placebo controlled, parallel group (2 groups), Proof of 
Concept (PoC) study that is designed to assess the efficacy, safety, and tolerability of SAR440340 
in patients with moderate-to- severe COPD on an establis hed LABA, LAMA and/or ICS 
background therapy (double or triple therapy) . Patients will be treated with SAR440340 or 
placebo for a minimum of 24 weeks and up to a maximum of 52 weeks*, and a 20-week safety 
follow-up period. 
*This study employs a variable treatment duration from 24 to 52 weeks to maximize data for the 
primary endpoint (annualized rate of exacerbation)  in a time-efficient manner. Patients enrolled 
in the trial will remain in the treatment period for up to a maximum of [ADDRESS_1226019] patient randomized completes a minimum treatment period of 24 weeks. Of note, the accrual and drop-out rates will be closely monitored. If the accrual rates are significantly lower than planned 
and/or the drop-out rates are higher than expecte d, the minimum treatment duration may be 
extended to achieve the desired amount of total exposure. The maximum treatment duration of 52 weeks will not be changed. 
The study duration is outlined below: 
• Screening period (10 days to 4 weeks)  
• Randomized IMP treatment period (24 to 52 weeks) 
• Post IMP safety follow-up treatment period (20 weeks). 
The randomization/baseline Visit is  defined as Day 1. The visit schedule should be adhered to 
within ±3 days for the screening period and rando mized IMP treatment period, and ±[ADDRESS_1226020] of Care background therapy, for 3 months prior to 
Visit 2/Randomization and at a st able dose for at least 1 month prior to the Screening Visit 1, 
including either: 
• Double therapy: LABA + LAMA or ICS + LABA or ICS + LAMA. 
OR 
• Triple therapy: ICS + LABA + LAMA. 
Patients who satisfy the inclusion and exclus ion criteria will be randomized (1:1) to:  
• SAR440340 (300 mg) administered as 2 SC injections every 2 weeks (q2w) for 24 to 52 
weeks  
• Matching placebo for SAR440340 administered as 2 SC injections q2w for 24 to 52 weeks  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 31 It is planned to enroll approximately 50% of patients on ICS-containing background therapy (ICS 
+ LABA; ICS + LAMA or ICS + LABA + LAMA). 
Patients must be willing to stay on their estab lished background medication for COPD throughout 
the duration of the study.  
Treatment discontinuation follow-up:  
Patients who withdraw from stud y treatment (prior to completing the planned duration of IMP 
treatment) will perform, as soon as possible, the early treatment discontinuation visit (ETD) with 
all assessments normally planned for the EOT visit, to assure a complete clinical assessment in 
close temporal proximity to the premature terminati on of study treatment is available. In addition, 
and to allow assessment of patient outcomes over the stipulated study period, patients will be asked and encouraged to complete all remaining study treatment visits, and participate in all safety follow-up assessments according to the visi t schedule with a +/-5 day window.  For such 
patients the assessment schedule will be reduced (See study flowchart for patients after permanent treatment discontinuation in Section  1.3.2) and alternate visits during the planned treatment period 
may be conducted by [CONTACT_648] (those with odd visit numbers, except for the planned EOT), as can visits F1 and F2.  
Under exceptional circumstances when a patient cannot come to the site for a scheduled visit, a 
phone contact [CONTACT_194276]. During the phone contact, at least information about AEs, 
concomitant medication a nd COPD exacerbation events should be collected. 
 Post IMP treatment follow-up: 
Upon completing the 24-52 weeks randomized IM P treatment, patients will continue their 
established ICS/LABA/LAMA therapy and en ter the 20-week safety follow-up period. 
4.[ADDRESS_1226021]-in-human study (R3500-HV-1551) to inves tigate safety and pharmacokinetics (PK) of a 
single intravenous (IV) infusion of 0.3, 1, 3 or 10 mg/kg or a single subcutaneous (SC) injection 
of 150 mg of SAR440340 in normal healthy volunteers was completed. Treatment with 
SAR440340 was generally well-tolerated. No deaths and no serious adverse events (SAEs) were 
reported. 
The first-in-patient study (R3500-AS-1619) to investigate safety, tolerability, PK, and 
pharmacodynamic (PD) effects of a repeated SC  administration of SAR440340 at 2 dose levels 
(75 and 150 mg), every week for 4 weeks, in adult patients with moderate asthma is ongoing, with 
all patients in the postdosing follow-up period. Un blinded safety data (a s of February 23, 2018) 
have demonstrated that SAR440340 is so far well tolerated. No SAE’s or deaths have been reported. 
A PD study (R3500-AS-1633) to assess the effects of a single IV dose of 10 mg/kg SAR440340, 
2 repeated SC doses of dupi[INVESTIGATOR_12458] (600 mg loading dose then 300 mg dose), and the coadministration of SAR440340 with dupi[INVESTIGATOR_877330] 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226022] been employed for recent studies with other biologics and are considered “state-of-the-art” 
for studies in COPD (7, 8). The selection of the dose of IMP and duration of study treatment are explained in Section  4.3 and Section  9.2, respectively.     
4.3 JUSTIFICATION FOR DOSE 
The dose regimen of SAR440340 selected for this  study is 300 mg SC administered every 2 
weeks (q2w).  This dosage regimen is predicted to achieve single-dose exposure which falls well within the maximum exposure achieved by [CONTACT_90975] 10 mg/kg IV dose shown to be safe in the FIH (R3500-HV-1551) single-ascending dose study.  Sa fety after repeated dose administration of 
SAR440340 can be inferred from the results of the chronic safety study in cynomolgus monkeys where doses as high as 100 mg/kg were administered weekly SC for 26 weeks. Based on systemic drug exposures (area under the concentration [AUC]-time curves) in the toxicology studies, the proposed SC dose of 300 mg q2w provides a safety  margin (exposure multip le based on predicted 
human exposure) of 13.7-29.8 for a proposed 24-52 week study. 
In addition to safety, PK-PD factors were c onsidered.  Based on modeling and simulation of 
SAR440340 HV-1551 FIH drug concentr ation, the 300 mg q2w regimen is expected to achieve a 
minimum concentration at steady state which is approximately 5-fold higher than the 
concentration of SAR440340 (17 mg/L) that showed efficacy consistently across all endpoints in an HDM-induced chronic lung inflammation mouse model.  The higher-fold exposure of the [ADDRESS_1226023] completed the study if he/she has completed all phases of the study including the end of study visit.  This st udy has a variable treatme nt period, therefore all 
participants who complete the planned treatment  period of [ADDRESS_1226024] visit which will occur at the 
end of a 20-week safety follow-up period for the fi nal patient(s) who complete(s) the study as per 
protocol.  
For patients who discontinue th e planned treatment, the recomme nded follow-up is described in 
Section  4.1. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 33 5 STUDY POPULATION 
Prospective approval of protocol  deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1 INCLUSION CRITERIA 
Participants are eligible to be included in the study only if all of the following criteria apply: 
Age 
Participant must be [ADDRESS_1226025] 1 year (based on Global Initiative for 
Chronic Obstructive Lung Dise ase [GOLD] definition, see (1). 
I 02. Participants with moderate-to-severe CO PD (post-bronchodilato r FEV1/forced vital 
capacity [FVC] <70% and post-bronchodilator FEV1 % predicted <80%, but ≥30%) at 
Visits [ADDRESS_1226026] (CAT) score ≥10 at Screening Visit 1 and 
Visit 2/Randomization.   
I 04. Participants with reported history of signs and symptoms of chronic bronchitis (chronic 
productive cough for 3 months in the year up to screening in a patient in whom other causes of chronic cough [eg, gastroesophageal reflux, chronic rhinosinusitis, bronchiectasis] have been excluded).  
I 05. Participants with a documented history  (eg. medical record verification) of ≥2 moderate 
exacerbations or ≥1 severe exacerbation within the year prior to screening 
- a moderate exacerbation is defined as an AECOPD requiring systemic corticosteroids (oral, intravenous, or intramuscular) and/or treatment with antibiotics (however, use of 
antibiotics alone does not qualify as a "mode rate exacerbation" unless documentation 
is available that use of antibiotics was necessary for treatment of worsening symptoms of COPD) 
- a severe exacerbation is defined as an AECOPD that required a hospi[INVESTIGATOR_059].  
I 06. Participants with Standard of Care background therapy, for 3 months prior to Visit 2/Randomization and at a stable dose for at least 1 month prior to the screening, including either: 
- Double therapy: LABA + LAMA or ICS + LABA or ICS + LAMA. 
OR 
Triple therapy: ICS + LABA + LAMA. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 34 I 07. Current or former smokers with a smoking history of ≥ 10 packs-year. 
Weight 
I 08. Body mass index (BMI) ≥18.0 kg/m2 (inclusive).  
Sex I 09. Male or Female 
See E 28 for required contraceptive measures. 
Informed  Consent 
I 10. Capable of giving signed informed consent as described in Appendix 1 ( Section 10.1.2) 
which includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol.  
5.2 EXCLUSION CRITERIA  
Participants are excluded from the study if any of the following criteria apply: 
Active comparator and/or mandatory background therapy  
E 01. Clinically significant abnormal electrocardiogram (ECG) at Visit [ADDRESS_1226027] of the study in the judgment of the Investigator. 
E 02.  Concomitant severe diseases or diseases for which the use of ICS (eg, active pulmonary tuberculosis [ E 07]) or LABA are contraindicated (eg, diagnosis of a history of significant 
cardiovascular diseases, insulin-dependent diabetes mellitus, hyperthyroidism, thyrotoxicosis, pheochromoc ytoma, hypokalemia).  
E 03.  Use of injectable glucocorticosteroids or oral  systemic glucocorticosteroids within 1 month 
prior to Visit 1/Screening or more than 4 courses of IV glucocorticosteroids within the 6 months prior to Visit 1. 
E 04. Participants receiving medications or th erapy that are prohibited as concomitant 
medications (see Section  6.5). 
E 05. A participant with a history of clinically significant renal, hepatic, cardiovascular, metabolic, neurologic, hematologic, ophthalmologic, respi[INVESTIGATOR_696], gastrointestinal, 
cerebrovascular or other significant medical illness or disorder which, in the judgment of the Investigator, could interfere with the stud y or require treatment that might interfere 
with the study. A specific example includes but is not limited to poorly controlled insulin-
dependent diabetes.  
E 06. Participants with Bronchial thermoplasty pr ocedure (up to 3 years prior to Visit 1). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 35 E 07. Exclusion related to tuberculosis (TB): 
• Active TB or a history of incompletely treated TB. 
• Confirmed Quantiferon-positive patients (no active disease) are excluded from the study 
unless the following conditions are met: 
- Patients with a history of prior documente d completed chemoprophylaxis for latent 
tuberculosis infection (with a treatment regimen as per local guidelines) or treatment of 
active TB infection, and 
- Has obtained consultation with a specialist to  rule out or treat active TB infection.  
• Suspected extrapulmonary TB infection. 
• Patients at high risk of contracting TB, such as close contact [CONTACT_877364]. 
Study Methodology  
E 08. The exclusion criterion was de leted (Amended Protocol 01). 
E 09. A current diagnosis of asthma according to the Global Initiative for Asthma (GINA) 
guidelines ( 13). 
E 10. Significant pulmonary disease other than COPD (eg, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchi ectasis, eosinophilic granulomatosis with 
polyangiitis, significant sleep apnea on Bilevel Positive Airway Pressure, etc) or another diagnosed pulmonary or systemic disease a ssociated with elevated peripheral eosinophil 
counts. 
E 11. Diagnosis of α-1 anti-trypsin deficiency. 
E 12. Advanced COPD with need for chronic (>15 hours/day) oxygen support. 
E 13. Participant with a modera te or severe AECOPD event (for definition, see Table 1 , primary 
objective) within [ADDRESS_1226028] infection within 
4 weeks prior to Screening/Visit [ADDRESS_1226029] omy or lung volume reduction surgery. 
E 16. Participants with a history of a systemic hypersensitivity reaction to a mAb drug. 
E 17. Anti-IgE therapy (eg, omalizumab [Xolair
®]) within 130 days prior to Visit 1 or any other 
biologic therapy (including anti-IL5 mAb, e.g. benralizumab [Fasenra®] or mepolizumab 
[Nucala®]) for asthma or systemic immunosuppressa nt (e.g., methotrexate) to treat other 
inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, syste mic lupus erythematosus, multiple sclerosis, 
etc) and other diseases, within 2 months or 5 half-lives prior to Visit 1, whichever is 
longer. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 36 E 18. Current history of substan ce and/or alcohol abuse. 
E 19. Inability to follow the procedures of the study (eg, due to language problems, 
psychological disorders) or unable to rea d, understand and fill a questionnaire or use an 
electronic diary without any help. 
E 20. Exposure to another investigative drug (s mall molecules as well as mAbs, including 
dupi[INVESTIGATOR_12458]) within a time period prior to Visit 1 that is <5 PK half-lives of the antibody. In case the half-life is not known, then the minimum interval since the exposure to the prior investigative antibody is 6 months. The min imum interval since exposure to any other 
(nonantibody) investigative study medi cation is 30 days prior to Visit 1. 
E 21. Patients who are participating in the acute phase of a pulmonary rehabilitation program, i.e. who started rehabilitation <4 weeks prior to screening (Note: patients in the maintenance phase of a rehabilitation program can be included). 
E 22. Clinically relevant (based on study Investigat or’s judgment) abnormal laboratory values 
suggesting an unknown disease and requiring further evaluation. 
E 23.  Participants previously treated in any clinical trial of SAR440340. 
E 24. Participant is the Investigator, or any Subinve stigator, research assistant, pharmacist, study 
coordinator, other staff or relative thereof di rectly involved in the conduct of the study. 
E 25.  Prisoners and participants who are legally institutionalized.  
Current knowledge of [COMPANY_011] compounds  
E 26. Known allergy to doxycycline or relate d compounds, or known allergy to SAR440340 
excipi[INVESTIGATOR_840]. 
E 27. Females who are lactating, breastfeeding or who are pregnant. 
E 28. For Women in the study
 
Women of childbearing potential (premenopau sal female biologically capable of 
becoming pregnant) who  
Do not have: 
• A confirmed negative serum β-human chorionic gonadotropin ( β-hCG) test at 
Visit 1. 
• Negative urine pregnancy test prior to Visit 2/Randomization. 
Who are not protected by [CONTACT_877365] 
(Appendix 4: Contraceptive guidance and collection of pregnancy information, see Section 10.4 ) (during the protocol-defined time frame from the signing of the ICF until the 
end of study visit). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 37 Postmenopausal women (defined as at least 12 consecutive months without menses) are 
not required to use a dditional contraception. 
For men in the study:  
Male participants with female partners of childbearing potential are not eligible to participate unless they agree to ONE of the following (during the protocol-defined time frame  [Appendix 4, Section 10.4 ]) 
• Are abstinent from penile-vaginal inte rcourse as their usual and preferred 
lifestyle (abstinent on a long term and pe rsistent basis) and agree to remain 
abstinent. 
• Agree to use a male condom plus partner use of a contraceptive method with a 
failure rate of <1% per year (Appendix 4, see Section  10.4) when having 
penile-vaginal intercourse with a woman of childbearing potential who is not 
currently pregnant. 
Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each epi[INVESTIGATOR_117492] 
(during the protocol-defined time frame from the signing of the ICF until the end of study visit). 
E 29. Diagnosed active parasitic infection (helminthes), suspected or high risk of parasitic infection, unless clinical and (if necessary) laboratory assessments have ruled out active 
infection before randomization. 
E 30. History of human immunodeficiency virus (HIV ) infection or positive HIV 1/2 serology. 
E 31. Known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, TB, histopl asmosis, listeriosis, coccidioidomycosis, 
penumocystosis, aspergillosis), despi[INVESTIGATOR_12468]; or unusually frequent, recurrent or prolonged infections , per Investigator’s judgment. 
E 32. Live, attenuated vaccinations within 12 weeks pr ior to Visit 1 or planned live, attenuated 
vaccinations during the study (see Appendix 7: List of prohibited live, attenuated vaccines, 
Section  10.7). 
E 33. Patients with autoimmune disease or patients using systemic immunosuppressive therapy for autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, et c) or patients with 
high titer autoantibodies at screening who are suspected of having high risk for developi[INVESTIGATOR_877331]. 
E 34. Patients with cardiovascular diseases/conditions: 
• Unstable ischemic heart disease, including acu te myocardial infarction within past [ADDRESS_1226030] 6 months.  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 38 • Cardiac arrhythmias including paroxysmal (eg, intermittent) atrial fibrillation are 
excluded. Patients with persistent atrial fibrillation as defined by [CONTACT_453572] 6 months and controlled with a rate control strategy (ie, selective β 
blocker, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) and 
stable appropriate level of an ticoagulation for at least 6 months may be considered for 
inclusion.  
• Cardiomyopathy, as defined by [CONTACT_877366]-IV (N ew York Heart Association) cardiac failure, 
or other relevant cardiovascular disorder th at in Investigator's judgment may put the 
patient at risk or negatively affect the study outcome 
• Uncontrolled hypertension (i.e. systolic blood pressure [BP] >180 mm Hg or diastolic BP >110 mm Hg despi[INVESTIGATOR_877332]-hypertensive therapy). 
E 35. Hepatitis B and/or C serologies indica tive of active or chronic infection. 
E 36. Any prior history of malignancy or active malignancy, including lymphoproliferative 
diseases (except successfully -treated carcinoma in-situ of the cervix, nonmetastatic 
squamous cell or basal cell carcinoma of the skin) within 5 years prior to Visit 2. 
E 37. Clinically significant laboratory tests at Screening/Visit 1: 
• Alanine transaminase (ALT) or aspartate transaminase (AST) >3 times upper limit of 
normal range (ULN). 
• Hemoglobin <10 g/dL for male and <9 g/dL for female. 
• Neutrophils <1.5 K/mm3 (<1 K/mm3 for those of African descent). 
• Platelets <100 K/mm3. 
• Creatinine ≥150 µmol/L. 
E 38. Patients on macrolide (eg, azithromycin) therap y, unless on stable therapy for >1 year. 
E 39. Patients on PDE-4 inhibitors (roflumilast) or leukotriene blockers (montelukast; Singulair etc). 
E 40. Despi[INVESTIGATOR_208450], enrollment/randomization is stopped at the study level. 
5.3 LIFESTYLE CONSIDERATIONS 
Not applicable  
5.4 SCREEN FAILURES 
Screen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomly assigned to IMP. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing require ments and to respond to queries 
from regulatory authorities. Minimal information includes demography, reason for screen failure, eligibility criteria, and any serious adverse event (SAE). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 39 Patients can be rescreened if they do not meet an exclusion criterion. Patie nts may be rescreened 
one time if they do not meet the eligibility criteria ( I 02) at the Screening Visit (Visit 1) or 
Randomization Visit (Visit 2) due to a spi[INVESTIGATOR_877333], or because the patient 
is unable to provide sufficient re producible efforts. Up to 3 total attempts during the screening 
visit (V1) are allowed for the reasons mentioned above. 
Patients who meet eligibility cr iteria (either meet an exclusi on criterion, or who do not meet ([ I 
02]) may be rescreened only once during the open screening period of the study; a different 
patient identification number will be issued. Rescreening is not permitted if the patient fails to meet inclusion criteria, except for I 02 (see Section  6.3.1). There is no requirement for a waiting 
period between the screen-failure date and the rescreening date. The IVRS/IWRS report will flag rescreened patients. Patients that are rescreened must sign a new consent form and all Visit [ADDRESS_1226031] be repeated. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 40 6 STUDY INTERVENTION 
The IMP includes SAR440340 and placebo for SC injection during the course of the study. 
6.1 STUDY INTERVENTION(S) ADMINISTERED 
Table [ADDRESS_1226032] 
(287 mg) is reconstituted by [CONTACT_877367] (not involved in any study 
related assessments/activities except 
preparation of IMP) with 2.5 mL of 
sterile water for injection resulting in 
2.9 mL of 100 mg/mL SAR440340. 
 A volume of 1.[ADDRESS_1226033] or 
designee (not involved in any study 
related assessments/activities except 
preparation of IMP) with 2.5 mL of 
sterile water for injection resulting in 
2.9 mL IMP.  
A volume of 1.5 mL per injection will be 
withdrawn from the vial. Patients will 
receive 2 injections per dose. 
Unit dose strength(s)/Dosage level(s) 300 mg Not applicable 
Route of administration Subcutaneous injection sites should 
alternate between the upper thighs, 4 
quadrants of the abdomen or the 
upper arms, so that the same site is 
not injected twice during consecutive 
visits Subcutaneous injection sites should 
alternate between the upper thighs, 4 
quadrants of the abdomen or the upper 
arms, so that the same site is not 
injected twice during consecutive visits 
Dosing instructions 14±3 days (q2w)  14±3 days (q2w) 
Packaging and labeling SAR440340 will be supplied in a glass 
vial packed in a kit box. Each kit box 
will be labeled as required per country 
requirement. Matched placebo will be supplied in a 
glass vial packed in a kit box. Each kit 
box will be labeled as required per 
country requirement. 
6.1.[ADDRESS_1226034](S) 
The investigational medicina l product (IMP) is administered every 14±3 days (q2w).  
Investigational medicina l product (IMP) will be administered by  [CONTACT_877368]. Patients should be monito red by [CONTACT_877369] 30 minutes after administration of a ll IMP injections. The monitoring period may be 
extended as per country specific or local site specific requirements. Trained personnel and 
medications should be available to  treat anaphylaxis or any severe allergic reaction if it occurs.  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226035](S) 
Background therapy  
Formulation: Dry powder inhaler (DPI), mete red dose inhaler (MDI) or pocket nebulizer 
Route(s) of administration: Oral inhalation 
Dose regimen: As prescribed. 
At Screening Visit 1, all patients must be on Standard of Care background therapy, for 3 months 
prior to Visit 2/Randomization and at a stab le dose for at least 1 month prior to the 
Screening/Visit 1, including either: 
• Double therapy: LABA + LAMA or ICS + LABA or ICS + LAMA. 
OR 
• Triple therapy: ICS + LABA + LAMA. 
Throughout the study, patients should continue their established background therapy for COPD. 
Patients must be willing to stay on their established background medication for COPD throughout 
the duration of the study. After successful management of an acute exacerbation of COPD (e.g. with oral corticosteroids and/or  antibiotics), all efforts should be made to resume the initial 
background COPD treatment regimen if in the inves tigator’s opi[INVESTIGATOR_877315]. 
After 1 severe or 2 moderate exacerbations of COPD, dose adjustments in background therapy 
will be permitted for symptom c ontrol and as needed for the remainder of the trial period. 
Reliever Medication 
Formulation: Dry powder inhaler (DPI), metere d dose inhaler (MDI) or pocket nebulizer  
Route(s) of administration: Oral inhalation 
Dose regimen: As prescribed. 
The reliever medication will not be dispensed or supplied by [CONTACT_1034]. Patients may administer albuterol/salbutamol or levalbuterol/levosalbutamol (including 
ipratropi[INVESTIGATOR_208411]/short-acting β agonists [SABA] combinations) as needed during the 
study. Nebulizer solutions may be us ed as an alternative delivery method. 
Study personnel will convert salbutamol/albut erol nebulizer, levosal butamol/levalbuterol 
nebulizer or ipratropi[INVESTIGATOR_208411]/short-acting β agonists [SABA] combination nebulizer, 
use as shown on the following tables:  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 42 Table 3 – Reliever Medication –Salbutamol/Albuterol Nebulizer Solution 
Salbutamol/Albuterol  Nebulizer Solution -Total Daily Dose (mg) Number of Puffs * 
2.5 4 
5.0 8 
7.5 12 
10 16 
*Conversion factor: Salbutamol/Albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs 
• Example of salbutamol/albuterol nebuliz er-to-puff conversion:  Patient received 
3 salbutamol/albuterol nebulizer treatments (2.5 mg/trea tment) between 7 and 11 AM. 
Total daily = 7.5 mg or 12 puffs. 
 
Table 4 - Reliever Medication - Levosalbutamol/Levalbuterol Nebulizer Solution 
Levosalbutamol/Levalbuterol Nebulizer Solution -Total Daily Dose (mg) Number of Puffs * 
0.63 2 
1.25 4 
2.5 8 
3.75 12 
5 16 
*Conversion factor:  levosalbutamol/levalbuterol nebulizer solution (1.25 mg) corresponds to 4 puffs 
• Example of levosalbutamol/leva lbuterol nebulizer-to-puff c onversion: Patient received 
3 levosalbutamol/levalbuterol nebulizer treatments (1.25 mg/treatment) between 7 and 
11 AM. Total daily = 3.75 mg or 12 puffs.  
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 43 Table 5 - Reliever Medication - Ipratropi[INVESTIGATOR_208405]/short-acting β  agonists [SABA] Nebulizer 
Solutions 
Total Daily Dose of Ipratropi[INVESTIGATOR_1890] (mg) in Ipratropi[INVESTIGATOR_714336]/SABA Nebulizer Solutions  Number of Puffs * 
0.5 4 
1.0 8 
1.5 12 
2.0 16 
*Conversion factor: ipratropi[INVESTIGATOR_208411]/short-acting β agonists (SABA)  nebulizer solution (with 0.5 mg 
Ipratropi[INVESTIGATOR_1890]) corresponds to 4 puffs 
• Example of ipratropi[INVESTIGATOR_877334]/short-acting β agonists [SABA] nebulizer-to-puff 
conversion: Patient received 3 ipra tropi[INVESTIGATOR_208411]/short-acting β  agonists [SABA] 
nebulizer treatments (0.5 mg Ipratropi[INVESTIGATOR_1890]/treatment) between 7 and 11 AM. Total daily = 
1.5 mg or 12 puffs. 
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY 
Storage and handling 
Investigators or other authorized persons (eg,  pharmacists) are responsible for storing the 
IMP/non-investigational medi cinal product (NIMP) in a secure a nd safe place in accordance with 
local regulations, labeling specifica tions, policies, and procedures.  
Control of IMP storage conditions, especially control of temperatur e (eg, refrigerated storage) and 
information on in-use stability and instructi ons for handling the [COMPANY_011] compound must be 
managed according to the rules provided by  [CONTACT_208533].  
The expi[INVESTIGATOR_125365] (when required by [CONTACT_125457]), and 
storage conditions are written on the IMP labels and in the instruction leaflet. 
1. The Investigator or designee must confirm ap propriate temperature conditions have been 
maintained during transit for all IMP received and any discrepancies are reported and resolved before use of the IMP. 
2. Only participants enrolled in the study may receive IMP and only authorized site staff may supply or administer IMP. All IMP must be stored in a secure, environmentally 
controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the Investigator and authorized site staff. 
3. The Investigator, institution, or the head of the medical institution (where applicable) is responsible for IMP accountability, reconcilia tion, and record maintenance (ie, receipt, 
reconciliation, and final disposition records). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226036] or designee (not involved in any study related assessments/activities except 
preparation of IMP) as per instruction provided in study pharmacy manual. 
Administration will be performed by [CONTACT_877370].  
Responsibilities 
The Investigator, the hospi[INVESTIGATOR_98341], or other personnel allowed to store and dispense the IMP will be responsible for ensuring that the IMP us ed in the clinical trial is securely maintained 
as specified by [CONTACT_328730]. 
All IMP will be dispensed in accordance with the Investigator's prescription and it is the Investigator's responsibility to ensure that an accurate record of IMP issued and returned is maintained. 
Any quality issue noticed with the receipt or us e of an IMP/NIMP/device (deficiency in condition, 
appearance, pertaining documentation, labeling, expi [INVESTIGATOR_320], etc) must be  promptly notified to 
the Sponsor. Some deficiencies may be re corded through a complaint procedure (see 
Section 8.3.8). A potential defect in the quality of IMP/NIMP/d evice may be subject to initiation of a recall 
procedure by [CONTACT_1034]. In this case, the I nvestigator will be res ponsible for promptly 
addressing any request made by [CONTACT_1034], in order to recall the IMP/NIMP/device and 
eliminate potential hazards. 
Under no circumstances will the Investigator supply IMP/NIMP/device to a third party, allow the 
IMP/NIMP/device to be used other than as directed  by [CONTACT_13129], or dispose of 
IMP/NIMP/device in any other manner. 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING 
6.3.[ADDRESS_1226037] (SAR440340 or matching pla cebo) will be packaged in accordance with the list. The 
[COMPANY_011] Clinical Supplies team will provide the randomized treatment kit number list to the centralized treatment a llocation system (Interactive Voice Response System [IVRS]/Interactive 
Web Response System [IWRS]). This centralized treatment allocation syst em will generate the 
patient randomization list according to which it will allocate the treatments to the patients. Patients who meet the entry criteria will be rando mized to receive either  SAR440340 or matching 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 45 placebo. The Investigator obtains treatment kit number at randomization and subsequent 
scheduled visits via an IVRS/IWRS that will be available 24 hours a day. Patients will be 
randomized in a 1:1 ratio to receive SC administrations of either: 
• SAR440340 300 mg q2w 
• Matching placebo for SAR440340. 
Investigational medicina l products will be dispensed at th e study visits summarized in SoA 
(Section  1.3).  
Returned IMP should not be re-dispensed to the participants. 
Patients can be rescreened if they do not meet an exclusion criterion. Patie nts may be rescreened 
one time if they do not meet the eligibility criteria ( I 02) at the Screening Visit (Visit 1) or 
Randomization Visit (Visit 2) due to a spi[INVESTIGATOR_877333], or because the patient 
is unable to provide sufficient re producible efforts. Up to 3 total attempts during the screening 
visit (V1) are allowed for the reasons mentioned above. 
Patients who meet exclusion criteria or who do not meet I 02 as specified above, may be 
rescreened only once during the open screening period of the study. Rescreening is not permitted 
if the patient fails to meet inclusion criteria (except for I 02 , as described above). For rescreening, 
see Section  5.4. 
Randomization will be st ratified by [CONTACT_6674]/Visit 1 eosinophil count (see below) and by 
[CONTACT_1606].  
To ensure scientific validity, alerts will be built into the IVRS/IWRS to control the number of 
patients enrolled into each stratification group, as follows: 
1. Eosinophil <250 /mm3: approximately 50 % (170) patients  
2. Eosinophil ≥250 /mm3: approximately 50 % (170) patients 
6.3.[ADDRESS_1226038] will be generated by [CONTACT_13225]. 
In accordance with the double-blind design, study pa tients, Investigators, and study site personnel 
(except the personnel who conduct the reconstitution of the IMP and preparation of syringes for 
injection) will remain blinded to study treatment and will not have access to the randomization 
(randomized treatment kit number) excep t under circumstances described in Section  6.3.3. 
To maintain blinding, the pers onnel involved with dose preparation will be required to agree not 
to reveal to other study personnel the type of IMP solution (SAR440340 versus placebo) in the 
vials/syringes.  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226039] only be broken in circumstances when knowledge of the IMP is 
required for treating the patient.  
Code breaking can be performed at any time by  [CONTACT_877371] (IRT) and/or by [CONTACT_877372]. If the blind is broken, the Investigator must document the date, time of day, and 
reason for code breaking.  
Patient withdrawal will only occur when the code break call is made at the site level, not the study 
level. This means that if the Emergency Unblindi ng transaction is performed by [CONTACT_737] 
(ie, at the site level), then the patient will be withdrawn from treatment. However, if the Emergency Unblinding transaction is performed by  [CONTACT_125460] (GSO) (ie, at the 
study level, as the GSO is not site based), then the patient will not be withdrawn from treatment. 
Patients who are withdrawn from tr eatment should be encouraged to remain in the study and the 
Investigator should discuss with them the key visits to attend (see Section  7.2). 
6.[ADDRESS_1226040] to verify accountability. 
Treatment kit number has to be recorded on the appropriate page of th e electronic Case Report 
Form (eCRF) and also on the product accountability and inventory form.  
All used, partially used, or unused treatments will be destroye d according to the standard practice 
at the site or per local regulations. A detailed treatment log of the IMP will be established with the 
Investigator or other personnel designated by [CONTACT_737], and countersigned by [CONTACT_179628]. Confirmation of destruction will be provided to the Sponsor. 
For NIMP not provided by [CONTACT_1034], tracking,  reconciliation and destru ction will be managed 
according to local regulation. 
6.5 CONCOMITANT THERAPY 
Any medication or vaccine (including over-the-c ounter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is  receiving at the time of enrollment or receives 
during the study must be recorded along with: 
• Reason for use 
• Dates of administration incl uding start and end dates 
• Dosage information including dose and frequency 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 47 The following concomitant treatments are not permitted during the screening or treatment phases: 
• Systemic steroids (except when used to treat exacerbations) 
Note: one short-term course of systemic corticosteroids (up to 6 days) is permitted in 24 
weeks, when medically necessary for reasons not related to AECOPD, eg. in the case of 
severe poison ivy exposure. 
• PDE-[ADDRESS_1226041]  
• Methylxanthines (theophylline, aminophyllines) 
• Leukotriene receptor antagonists or leukotriene synthesis inhibitors 
• Lipoxygenase inhibitors 
• Anti-IL5 mAb (eg, benralizumab; mepolizumab) 
• Anti-IgE therapy (eg, omalizumab)  
• Anti-IL4R mAb (eg, dupi[INVESTIGATOR_12458]) 
• Systemic immunosuppressants (e g, methotrexate, any anti-TNF mAbs, B and/or T cell 
targeted immunosuppressive therapi[INVESTIGATOR_014]) 
• Bronchial thermoplasty  
• Intravenous immunoglobulin (IVIG) therapy 
• Live Attenuated Vaccines: refer to Appendix 7: List of Prohibited Live Attenuated Vaccines,  Section  10.7. 
• β-adrenergic receptor blockers (except for a selective β-1 adrenergic receptor blocker used 
with dose stable 1 month prior to Visit 1) 
• COPD relievers other than salbutamol/albuterol, levosalbutamol/levalbuterol or ipratropi[INVESTIGATOR_1890]: their use is not recommended du ring the study period. In case of use in 
exceptional circumstances (eg, prescribed by a physician not participating in the study), 
their use will be documented in the patient's file and reported in the eCRF. 
• Other investigational drugs 
Note:  The following is a list of permitted concomitant medications during the study: 
• Antihistamines are permitted as concomitant medication 
• Ocular, intranasal, and topi[INVESTIGATOR_877335]. 
6.6 DOSE MODIFICATION 
Not applicable for this study.  
6.7 INTERVENTION AFTER THE END OF THE STUDY 
Not applicable 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 48 7 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL 
Withdrawal of consent for treatme nt (ie, treatment discontinuati on at patient request) should be 
distinguished from (additional) wit hdrawal of consent for follow-up visits and from withdrawal of 
consent for non-patient contact [CONTACT_6492]-up (eg, me dical record checks). The site should document 
any case of withdrawal of consent. 
7.1 DISCONTINUATION OF STUDY INTERVENTION  
The IMP should be continued whenever possible.  
In case the IMP is stopped, it should be determined  whether the stop can be made temporarily; 
permanent IMP discontinuation should be a last resort. Any IMP discontinuation must be fully 
documented in the CRF or eCRF. In any case, the patient should remain in the study as long as 
possible. 
7.1.[ADDRESS_1226042] of criteria for permanent treatment discontinuation 
The patients may withdraw from treatment with the IMP if they decide to do so, at any time and irrespective of the reason, or this may be the Inve stigator’s decision. All efforts should be made to 
document the reason(s) for treatme nt discontinuation and this shoul d be documented in the eCRF. 
Patients must be withdrawn from the study for the following reasons: 
• At their own request or at the request of th eir legally authorized representative (legally 
authorized representative means an individual or judicial or other body authorized under 
applicable law to consent on beha lf of a prospective patient to the patient's participation in 
the procedure(s) involved in the research). 
• If, in the Investigator's opi[INVESTIGATOR_1649], continuation in the study would be detrimental to the patient's well-being. 
• At the specific request of the Sponsor. 
• In the event of a protocol deviation, at the discretion of the Investigator or the Sponsor. 
• Pregnancy. 
• Anaphylactic reaction or systemic allergic reactions or acute allergic reactions that are related to IMP and require immediate treatment (Appendix 14: Definition of anaphylaxis, see Section  10.15). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 49 • Diagnosis of a malignancy during study, excluding carcinoma in situ of the cervix, or 
squamous or basal cell carcinoma of the skin. 
• Any situation that meets permanent discontinuation rule as outlined in Appendix 6: Liver and other safety: suggested actions and follow-up assessments (Appendix 6, Section 10.6). 
• Any opportunistic infection, such as TB or ot her infections whose nature or course may 
suggest an immunocompromised status (Appendi x 15: List of Opportunistic Infections, 
See Section  10.16). 
• Serum ALT >[ADDRESS_1226043] and total bilirubin >[ADDRESS_1226044] (Appendix 6, see Section  10.6). 
• Serum ALT >[ADDRESS_1226045] if baseline ALT ≤[ADDRESS_1226046] or ALT >[ADDRESS_1226047] if baseline ALT >[ADDRESS_1226048] 
(Appendix 6, see Section  10.6). 
Any abnormal laboratory value or ECG para meter will be immediately rechecked for 
confirmation before making a decision of perman ent discontinuation of the IMP for the concerned 
patient. 
See the SoA ( Section  1.3.2) for data to be collected at the time of intervention discontinuation and 
follow-up and for any further evaluati ons that need to be completed. 
Handling of participants after perm anent intervention  discontinuation  
Patients who withdraw from stud y treatment (prior to completing the planned duration of IMP 
treatment) will perform, as soon as possible, the early treatment discontinuation visit (ETD) with 
all assessments normally planned for the EOT visit, to assure a complete clinical assessment in 
close temporal proximity to the premature terminati on of study treatment is available. In addition, 
and to allow assessment of patient outcomes over the stipulated study period, patients will be asked and encouraged to complete all remaining study treatment visits, and participate in all safety follow-up assessments according to the visi t schedule with a +/-5 day window.  For such 
patients the assessment schedule will be reduced (See study flowchart for patients after permanent treatment discontinuation in Section  1.3.2) and alternate visits during the planned treatment period 
may be conducted by [CONTACT_648] (those with odd visit numbers, except for the planned EOT), as can visits F1 and F2.  
Under exceptional circumstances when a patient cannot come to the site for a scheduled visit, a 
phone contact [CONTACT_194276]. During the phone contact, at least information about AEs, 
concomitant medication a nd COPD exacerbation events should be collected. 
Participants will be followed-up according to the study procedures specified in this protocol up to the scheduled date of study completion (ie, EOS, see Section  1.3), or up to recovery or 
stabilization of any AE to be followed-up as specified in this protocol, whichever comes last. 
All cases of permanent treatment discontinuation mu st be recorded by [CONTACT_877373] e CRF when considered as confirmed. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226049] anned for the subsequent visit (excluding 
randomization and EOT). Reinitiation of trea tment with the IMP will be done under close and 
appropriate clinical/and or laboratory monitoring once the Investigator will have considered 
according to his/her best medical judgment that th e responsibility of the IMP(s) in the occurrence 
of the concerned event was unlikely and if the selection criteria for the study are still met (refer to   Section  5.1 and Section  5.2). For all temporary treatment di scontinuations, duration must be 
recorded by [CONTACT_877374]. 
Following a temporary interruption or a missed dose, the IMP treatment should be reinitiated at 
the next scheduled visit, maintaining the original dosing schedule.  
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY 
A participant may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons. 
• If the participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent. 
• If a participant withdraws from the study, he /she may request destru ction of any samples 
taken and not tested, and the Inve stigator must document this in the site study records. The 
investigator should also inform the Sponsor that appropriate actions are taken regarding 
these samples. 
• See SoA (Section  1.3.2) for data to be collected at the time of study discontinuation and 
follow-up and for any further evaluati ons that need to be completed. 
Patients who withdraw from stud y treatment (prior to completing the planned duration of IMP 
treatment) will perform the ETD visit and will be asked and encouraged to complete all remaining study treatment visits (For details, see Section  1.3.2 and Section  7.1.1). The value of all their 
study data collected during their continued involvement will be emphasize d as important to the 
public health value of the study. 
All study withdrawals should be recorded by [CONTACT_877375] e-CRF and in the patient’s medical records. In the medical record, at least the date of the 
withdrawal and the reason should be documented. In addition, a patient may withdraw  his/her consent to stop particip ating in the study. Withdrawal 
of consent for intervention should be distingu ished from withdrawal of consent for follow-up 
visits and from withdrawal of consent for non- patient contact [CONTACT_6492]-up, eg, medical record 
checks. The site should document any case of withdrawal of consent. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226050] withdrawn from the study cannot be re-randomized/reallocated (treated) in 
the study. Their inclusion and interv ention numbers must not be reused.  
7.[ADDRESS_1226051] be taken if a participant fails to return to the clinic for a required study 
visit: 
• The site must attempt to cont act the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit schedule and ascertain whether or not the partic ipant wishes to and/or should continue in 
the study. 
• Before a participant is deemed lost to follo w up, the Investigator or designee must make 
every effort to regain contact [CONTACT_877376] (where possible, 3 telephone calls and, if 
necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These c ontact attempts should be documented in the participant’s 
medical record. 
• Should the participant continue to be unreach able, he/she will be considered to have 
withdrawn from the study.  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 52 8 STUDY ASSESSMENTS AND PROCEDURES 
Study procedures and their timing are summarized in the SoA ( Section  1.3). Protocol waivers or 
exemptions are not allowed. 
• Immediate safety concerns should be di scussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
IMP. 
• Adherence to the study design requirements, including those specified in the SoA, is essential and require d for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The Investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.  
Procedures conducted as part of the participant’s routine clinical management (eg, blood count) 
and obtained before signing of the ICF may be utilized for screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within the time frame defined in the SoA ( Section  1.3). 
8.1 EFFICACY ASSESSMENTS  
8.1.1 Disease-specific efficacy measures  
[IP_ADDRESS] COPD exacerbation 
 
Severity of COPD exacerbations  as defined by [CONTACT_760] 
 
“Moderate exacerbations” are recorded by [CONTACT_877377] (such as intramuscular, intravenous or oral) and/or antibiotics. 
“Severe exacerbations” are recorded by [CONTACT_208529][INVESTIGATOR_059], emergency medical care visit or resulting in death.  
 
All other exacerbations will be  classified as “mild”. 
 
Clinical symptoms of exacerbations of COPD 
 
In addition to the protocol-defined exacerbatio ns of COPD listed a bove, clinical signs and 
symptoms of exacerbations of COPD will be capt ured in the eCRF (including, but not limited to 
increase in dyspnea, increase in wheezing, increase in cough, increase in sputum volume and/or 
increase in sputum purulence). 
 
Management of exacerbations of COPD 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 53 Exacerbations of COPD should be treated as deemed necessary by [CONTACT_093]. After 
successful management of an acute exacerbation of COPD (e.g. with oral corticosteroids and/or antibiotics), all efforts should be  made to resume the initial b ackground COPD treatment regimen 
if in the investigator’s opi[INVESTIGATOR_877336]. After 1 severe or 2 moderate 
exacerbations of COPD, dose adjustments in b ackground therapy will be permitted for symptom 
control and as needed for the remainder of the trial period. 
Protocol defined COPD exacerbation events are collected as efficacy endpoints via the exacerbation eCRF page. These events should not  be reported as AEs unless they fulfill a 
seriousness criterion. Any course of systemic steroids/antibiotics st arted <7 days of finishing a 
previous course should be considered as  treatment for a single exacerbation. 
[IP_ADDRESS] Spi[INVESTIGATOR_877337] (ERS)/American Thoracic Society (ATS) guidelines ( 14) and prior to 
administration of inve stigational product.  
For pre-bronchodilator measured parameters, incl uding FEV1, peak expi[INVESTIGATOR_10229] (PEF), FVC 
and forced expi[INVESTIGATOR_10229] (FEF) 25%-75%, spi[INVESTIGATOR_208460] a wash out  period 
of bronchodilators according to their action duration, for example, withhol ding the last dose of 
salbutamol/albuterol or levosalbutamol/levalbuterol for at least [ADDRESS_1226052] 12 hours (ultra-long acting LA BA like vilanterol should be withheld for at 
least 24 hours), withholding the last dose of ipra tropi[INVESTIGATOR_208461] [ADDRESS_1226053] 24 hours. Th is will be verified before performing the 
measurements.  
Note: When both pre- and post-bronchodilator sp irometry is assessed, the post-bronchodilator 
spi[INVESTIGATOR_714304] (ie, 
30 minutes for albuterol or other SABA). 
At all visits, spi[INVESTIGATOR_877338]; afternoon/evening is 
allowable in the exceptional circumstance when morning spi[INVESTIGATOR_125375]; 
spi[INVESTIGATOR_208464]. 
Current smokers need to be reminded not to smoke for at least [ADDRESS_1226054] spi[INVESTIGATOR_181201], including calibration, will be used to perform spi[INVESTIGATOR_877339], whenever possible, the same person should perform the 
measurements. 
Three measurements fulfilling the ATS acceptability and repeatability criteria should be obtained 
at every visit, if possible.  
Further details on spi[INVESTIGATOR_181203] a separate operational manual provided to the 
sites. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 54 [IP_ADDRESS] Optional Fractional exhaled nitric oxide (FeNO)  
Fractional exhaled nitric oxide (FeNO) will be analyzed using a NIOX instrument (Aerocrine AB, 
Solna, Sweden), or similar analyzer using a flow rate of 50 mL/s, and reported in parts per billion (ppb). This assessment should be c onducted prior to spi[INVESTIGATOR_125392] a fast of at least 1 
hour. Further details on the procedure for measur ing exhaled nitric oxide with NIOX will be 
provided in a separate  instruction manual. 
FeNO will be measured at sites only with access to FeNO equipment. 
[IP_ADDRESS] Disease-specific, daily efficacy assessments 
See Patient Reported Outcomes (Section  8.1.2) 
[IP_ADDRESS] Optional actigraphy and home spi[INVESTIGATOR_877340] (sleep and activity) and home spi[INVESTIGATOR_714346]. Patient will be issued an actigraphic wristband and asked to wear it continuously (including at night) throug hout three monitoring periods defined in study 
flowchart ( Section  1.3) on the nondominant hand, including at night. The actigraphic data is used 
to measure sleep parameters and daytime activity. The actigraph will be worn during the screening period as well as two monitoring periods during the treatment phase. Data from the device will be uploaded to a computer at each clinic  visit following a monitoring period. 
Patients will receive documented in -clinic training for use of ambulatory at-home spi[INVESTIGATOR_877341]. During the study patients will be required to use at-home spi[INVESTIGATOR_877342]1. Patients will be instructed to perform expi[INVESTIGATOR_877343] y between 06:00 and 12:00 hour and 
between 18:00 and 24:00 hour during the screenin g period and for 2 week intervals during the 
treatment and follow-up period as indicated in the study flowchart. 
[IP_ADDRESS] Optional Sputum Collection 
A subset of study sites will be selected to perf orm evaluations of induced sputum, and patients at 
these selected sites will have th e option to participate in this assessment. Sputum induction is a 
relatively noninvasive method to obtain sputum for cell or fluid phase inflammatory indices, culture or cytology. It is performed with an aero sol of normal or hypertoni c saline generated by [CONTACT_877378]. As this aerosol is a potentia l bronchoconstrictive stimulus , it is made safe by 
[CONTACT_877379] a dose res ponse manner. Collection will be 
performed according to protocol flowchart. 
Further details will be provided in the site procedure manual.
  
8.1.2 Patient reported outcomes questionnaires 
At screening (Visit 1), patients will be issued an electronic diary. Patients will be instructed on the 
use of the device, and written instructions on the use of the electronic device will be provided to 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 55 the patients. Recorded information is downloade d from this device on the other indicated days 
(Section  1.3).  
On a daily basis during screen ing and treatment, the patient uses an electronic diary to: 
• Respond to the COPD symptom scale questions of the EXACT tool 
• Record the daily use of COPD reliever medication 
• Record use of systemic corticosteroids and/or antibiotic s taken for COPD exacerbation. 
The electronic diary will be used for pa tient reported outcome  questionnaires.  
In the Post IMP Treatment Period, the patient's  response in the electronic diary will not be 
recorded daily; questionnaires will only be administered at on-site vis its. When completed at 
study site, PRO assessments should be completed as part of the visit (per SoA, Section  1.3) but 
prior to any meaningful communication with a health care professional or any other study 
procedures. 
[IP_ADDRESS] COPD Assessment Test (CAT) 
The CAT (15) is a new questionnaire that is designed for patients with COPD to measure the 
effects of the disease on their quality of lives. The CAT™ is an 8-item self-administered 
questionnaire which has been developed for use in routine clinical practice to measure the health 
status of patients with COPD (see Appendix 10: COPD Assessment Test, Section  10.11).  
The CAT™ score ranges from [ADDRESS_1226055] tightne ss, dyspnea, activity limitation, confidence, sleep 
and energy ( 16). Patients scored questions from 1-5 acco rding to their own feelings about the 
disease (1 = I am very happy; 5 = I am very sad). 
[IP_ADDRESS] St. George's Respi[INVESTIGATOR_6015] (SGRQ) 
The St. George's Respi[INVESTIGATOR_6015] (SGRQ [( 17), ( 18)]) is a 50-item questionnaire 
designed to measure and quantify health-related health status in adult patients with chronic 
airflow limitation. A global score ranges from 0 to  100. Scores by [CONTACT_877380]: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. Lower score indicates better quality of life (QoL) (see  Appendix 11: St. George's Respi[INVESTIGATOR_6004], Section  10.12).  
The first part ("Symptoms") evaluates symptoma tology, including frequency of cough, sputum 
production, wheeze, breathlessness and the duration a nd frequency of attacks of breathlessness or 
wheeze. The second part has two components: "Ac tivity" and "Impacts". The "Activity" section 
addresses activities that cause breathlessness or are limited becau se of breathlessness. The 
"Impacts" section covers a range of factors incl uding influence on employment, being in control 
of health, panic, stigmatization, the need for me dication, side effects of prescribed therapi[INVESTIGATOR_014], 
expectations for health and disturbances of dail y life. The recall period of the questionnaire is over 
the past 4 weeks.  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 56 Psychometric testing has demonstrated its repeatability, reliability and validity. Sensitivity has 
been demonstrated in clinical trials. A minimum change in score of 4 units was established as clinically relevant after patient and clinician testing. The SGRQ has been used in a range of disease groups including asthma, COPD and bronchiectasis. 
[IP_ADDRESS] Exacerbations of chronic obstructive pulmonary disease tool (EXACT) 
The EXACT Total Score measures symptoms of acute bacterial exacerbations of chronic bronchitis-COPD (ABECB-COPD), ie, an acute, sustained, and worsening of signs and symptoms beyond day-to-day variability (see Appendix 12: Exacerbations of Chronic obstructive pulmonary disease tool [EXACT], Section  10.13). The instrument’s total score is made up of a total of 14 
items representing the following domains: 
• Breathlessness (5 items), 
• Cough and sputum (2 items), 
• Chest symptoms (3 items), 
• Difficulty bringing up sputum (1 item), 
• Tired or weak (1 item), 
• Sleep disturbance (1 item), and 
• Scared or worried (1 item). 
The EXACT is a daily diary, completed each evening before bedtime. The instrument was developed with e-diary administration in mind, with cognitive interviews performed with paper pen booklet and personal digital assistant (PDA) to document respondent understanding in either mode and user acceptance of the PDA. 
[IP_ADDRESS] Euro Quality of Life-5 Dimension questionnaire (EQ-5D) 
EQ-5D-5L is a standardized health-related QoL questionnaire developed by [CONTACT_159872] a simple, generic measure of health for clinical a nd economic appraisal ( 19). 
EQ-5D is designed for self-completion by [CONTACT_490178], (Appendix 13: Euroquol Questionnaire, see 
Section  10.14). 
8.[ADDRESS_1226056] (AESI), will be collected at 
every visit. The assessments for AE, SAE and AESI are described in Section  8.3. 
Planned time points for all safety assessments are provided in the SoA ( Section  1.3). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 57 8.2.1 Physical examinations 
A complete physical examinations will include skin, nasal cavities, eyes, ears, respi[INVESTIGATOR_696], 
cardiovascular, gastrointestinal , neurological, lymphatic, and musculoskeletal systems. All 
deviations from normal will be recorded, including those attributable to the patient’s disease. 
Refer to Section  1.3 for the schedule of physical examina tions performed throughout this study. 
Investigators should pay special attention to clinic al signs related to previous serious illnesses or 
signs of infection.  Any new clinically significant finding or worsenin g of previous finding should be reported as a 
new adverse event. 
8.2.2 Vital signs 
Vital signs, including systolic and diastolic BP (mmHg), pulse rate (beats per minute), body 
temperature (°C), and respi[INVESTIGATOR_148235], baseline and every 
subsequent on-site visit. Height (cm) will be measured at Screening (Visit 1) only. Body weight (kg) will be measured at Screening (Visit 1) and EOT/EOS visits. 
Vital signs will be measured in the sitting position using the same arm (preferably), at each visit 
detailed in the SoA ( Section  1.3), and will be measured prior to receiving investigational product 
at the clinic visits.  
8.2.[ADDRESS_1226057] ad ministration. A minimum of 3 complexes in an 
appropriate lead (lead II) will be averaged to determine the PR-interval, QT/QTc-interval, QRS-complex and heart rate will be measured for each ECG. Refer to ECG reading manual for more details. All ECG recordings will be centrally read by [CONTACT_208548]. 
8.2.4 Clinical safety laboratory assessments 
The clinical laboratory tests are planned to  be conducted at a central laboratory.  
See Appendix 2: Clinical Laboratory Tests ( Section  10.2) for the list of clinical laboratory tests to 
be performed and to the SoA ( Section  1.3) for the timing and frequency.  
• The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be f iled with the source documents. Clinically significant 
abnormal laboratory findings are those which are not associated with the underlying 
disease, unless judged by [CONTACT_78782]'s condition. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 58 • All laboratory tests with values considered clinically signifi cantly abnormal during 
participation in the study or within [ADDRESS_1226058] dose of IMP should be repeated 
until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_113543]. 
- If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_737], the etiolo gy should be identified and the Sponsor 
notified. 
All protocol-required labo ratory assessments, as defined in Appendix 2 ( Section  10.2), must be 
conducted in accordance with the la boratory manual and the SoA.  
- If laboratory values from non-protocol speci fied laboratory assessments performed at 
the institution’s local laboratory require a change in participant management or are considered clinically significant by [CONTACT_3433] e Investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the CRF.  
The clinical laboratory parameters that will be measured are described in Appendix 2: Clinical laboratory tests ( Section 10.2 ). Decision trees for the management of certain laboratory 
abnormalities by [CONTACT_877381] d in Appendix 6: Liver and Ot her Safety: Suggested Actions 
and Follow-up Assessments ( Section  10.6). 
For patient(s) who have consented to it, the samp les that are archived, unused or left over after 
planned testing may be used for additional re search purposes (Appendix 16: Future Use of 
Samples, see Section  10.17). 
8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
The definitions of an AE or SAE can be found in Appendix 3: Adverse Events: Definitions and 
Procedures for Recording, Evaluating, Follow-up, and Reporting ( Section  10.3). 
AE will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).  
The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the IMP or study procedures, or that caused the 
participant to discontinue the IMP (see Section  7).  
8.3.[ADDRESS_1226059] (AESI) is an AE (serious or nonser ious) of scientific and 
medical concern specific to the Sponsor’s product or program, fo r which ongoing monitoring and 
immediate notification by [CONTACT_56481] e Sponsor is required. Such events may require 
further investigation in order to characterize and understand them. Adverse events of special interest may be added, modified or removed during a study by [CONTACT_12548]. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 59 For these AESIs, the Sponsor will be inform ed immediately (ie, within 24 hours), per SAE 
notification described Section  8.3.2, even if not fulfilling a seriousness criterion, using the screens 
in the eCRF. 
Anaphylactic reactions, systemic allergic reactions that require treatment (refer to Section  10.15 
for definition of anaphylaxis). 
• Anaphylactic reactions, systemic allergic reactions that require treatment (refer to 
Section 10.15 for definition of anaphylaxis). 
• Severe injection site reactions (I SR) that last longer than 24 hours 
Note: A severe ISR (for AE reporting) is any event that meets one of the following criteria: 
- With a diameter of at least 10 cm. 
- Impacting daily activities. 
- With ulceration or necrosis.  
- For which operative intervention is required. 
• Any infection meeting at least one of the following criteria: - Any serious infection (SAE). 
- Requires parenteral (IV, intramuscular, SC) antimicrobial therapy  
Note:  Antimicrobial therapy refers to antibiotic, antiviral, and antifungal agents. 
- Requires oral antimicrobial therapy for longer than 14 days. 
- Is a parasitic infection. 
- Is an opportunistic infection (see Appendix 15: List of Opportunistic Infections, 
Section  10.16). 
• Significant ALT elevation. 
- ALT >3 x the upper limit of normal (ULN) asso ciated with Total Bilirubin >[ADDRESS_1226060]; 
or 
- ALT >[ADDRESS_1226061] in patients with baseline ALT ≤[ADDRESS_1226062]; or 
- ALT >[ADDRESS_1226063] if baseline ALT >[ADDRESS_1226064]. 
• Malignancy 
• Pregnancy of a female patient entered in a study as well as pregnancy occurring in a 
female partner of a male patient entered in a study with IMP/NIMP;  - Pregnancy occurring in a female patient entered in the clinical trial or in a female 
partner of a male patient entered in the clinical trial. It will be qualified as an SAE only if it fulfills one of the seriousness criteria (see Appendix 3 [ Section  10.3]). 
- In the event of pregnancy in a female participant, IMP should be discontinued.  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 60 - Follow-up of the pregnancy in a female partic ipant or in a female partner of a male 
participant is mandatory until the outcome has been determined (Appendix 4: 
Contraceptive guidance and collecti on of pregnancy Information, see Section  10.4) 
- Abnormal pregnancy outcomes (eg, spontan eous abortion, fetal death, stillbirth, 
congenital anoma lies, ectopic pregnancy) are considered SAEs. 
• Symptomatic overdose (serious or nonseri ous) with IMP/noninves tigational medicinal 
product (NIMP) 
- An overdose (accidental or intentional) with the IMP is an event suspected by [CONTACT_495574] (not based on systematic pi[INVESTIGATOR_12988]) and defined as at least twice the intend ed dose during an interval of <8 days.  
“The circumstances (ie, accide ntal or intentional) should be clearly specified in the 
overdose form”. 
- An overdose (accidental or intentional) with any NIMP is an event suspected by [CONTACT_877382] e patient and defined as at least twice the 
maximum daily dose as specified in a drug label, within the intended therapeutic interval. “The circumstances (i e, accidental or intentional)  should be clearly specified 
in the overdose form”.  
- Of note, asymptomatic overdose has to be reported as an AE. 
Table [ADDRESS_1226065] therapeutic mAbs. 
Acute allergic reactions may be defined as allergic  reaction-mediated signs and symptoms experienced by 
[CONTACT_877383]. These reactions may present in a 
variety of ways, including dizziness, headache, anxiety, dyspnea, hypotension, tachycardia, pruritus, rash, 
urticaria/angioedema, flushing, nausea, or vomiting. Anaphylaxis may represent the most severe form of allergic reaction, but these events may also o ccur via non-IgE mediated mechanisms (eg, anaphylactoid 
reactions), or may occur via other immune-mediat ed mechanisms (eg, cytokine-mediated). Allergic 
reactions may begin within a few hours and persist up to [ADDRESS_1226066] dosing. Refer to Section 10.15 
“Definition of Anaphylaxis”, which describes the clinical criteria for the diagnosis of anaphylaxis. Delayed onset or late phase hypersensitivity reactions (ie, Type 1 hypersensitivity reaction) may manifest between 
[ADDRESS_1226067] be reported as an AESI with immediate notification 
(for further details, see Table 7). If an anaphylactic reaction, systemic allergic reaction requiring treatment 
occurs and is considered related to IMP by [CONTACT_877384]. 
Anti-drug antibodies and PK samples will be collected near the onset and resolution of the AESI for any 
additional analysis. 
Severe injection 
site reactions Based on the SC mode of administration of high doses of  protein ISRs are considered as a potential risk for 
SAR440340.  
Patients who experience an ISR must be closely monitored for the possibility of a more intense ISR with a 
future injection. Any severe ISR that lasts ov er 24 hours will be reported as an AESI with immediate 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 61 notification (for further details please see Table 7). Anti-drug antibodies and PK samples will be collected 
near the onset and resolution of the AESI for any additional analysis 
If there is any consideration being  given to premedicating before the next dose (for preceding an injection 
site reaction, please contact [CONTACT_877385]). 
Infections, including 
opportunistic infections Some biologic therapi[INVESTIGATOR_877344], including opportunistic 
infection.  
IL-33 is a proinflammatory cytokine released by [CONTACT_877386][INVESTIGATOR_877345], viruses, or bacteria. IL-33 signaling initiates and amplifies multiple downstream inflammatory 
pathways resulting in effects characteristic of  both type 1 and type 2 immune inflammations. Although 
blockade or knockout of IL-33 signaling in mice di d not reveal any unique role for IL-33 in mounting an 
acute immune response to viral challenge and did not lead to worsening of symptoms or outcome, patients will be monitored for signs or symptoms of infection. 
SAR440340 inhibits the T-helper 2 (Th2)  cytokines production. Infections with a diversity of helminthic 
parasites elicit eosinophilia via stimulation of Th2-like lymphocyte responses. The Th2 response is 
characterized by [CONTACT_181290]4, IL13, and IL5, subsequently generating IgG1 and IgE-secreting cells, 
and eliciting eosinophilia. Eosinophilia is prominent in  a number of helminthic parasitic diseases. The 
eosinophilic response to helminths is determined both by [CONTACT_40689]'s immune response and by [CONTACT_181291], 
including its distribution, migration, and development within the infected host. Therefore, patients treated 
with SAR440340 may potentially have an increased risk of parasitic infection.  
To minimize the risk, patients with certain type of infe ctions are not allowed to participate in the study (eg, 
patients with active opportunistic or parasitic infections or at high risk of developi[INVESTIGATOR_877346], patients 
with medical history of invasive opportunistic infecti ons, patients with HIV infection or HIV seropositivity, 
patients with positive screening for hepatitis B and C). 
As a precautionary measure, the Investigator is requir ed to carefully monitor for any signs or symptoms of 
infection such as, but not limited to, increased body temperature, malaise, weight loss, sweats, cough, 
dyspnea, pulmonary infiltrates, or serious febrile systemic illness. 
During the study, appearance of signs or symptoms (s uch as abdominal pain, cough, diarrhea, fever, 
fatigue and hepatosplenomegaly) that could be associated with a parasitic infection should be carefully 
evaluated, especially if there is a history of parasit ic exposure through recent travel to/or residence in 
endemic areas, especially when conditions are conducive to infection (eg, extended stay, rural or slum 
areas, lack of running water, consumption of uncooked, undercooked, or otherwise potentially 
contaminated food, close contact [CONTACT_181292], etc). Subsequent medical assessments (eg, 
stool exam, blood tests, etc) must be performed in order  to rule out parasitic infection/infestation.  
Infections defined in Section 8.3.1  should be reported as AESIs with immediate notification. A complete 
diagnostic work-up should be performed (ie, cultures, histopathological or cytological evaluation, antigen 
detection and serum antibody titers). Patients should be referred to an infectious disease specialist if 
deemed necessary for diagnostic work up and appropriate treatment. 
Infections or infestations that do not respond to medical treatment should have study drug discontinued 
until the infection is resolved.  
For any opportunistic infection, such as TB, or other infections whose nature or course may suggest an 
immunocompromised status (see Section 10.16), patients must be permanently discontinued from study 
medication. 
Elevated liver function tests No preclinical and clinical data has suggested any hepat ic toxicity of SAR440340; however, as a general 
consideration of clinical development, the administration of immunosuppre ssant or immunomodulating 
agents may represent an additional risk factor for hepatotoxicity.  
In order to closely follow liver function tests (LFT), assessment of total protein, albumin, total bilirubin (in 
case of values above the normal range, different iation in conjugated and nonconjugated bilirubin), alanine 
aminotransferase, aspartate aminotransferase, and alkaline phosphatase are measured as part of the 
clinical laboratory testing. 
Guidance for the investigation of elevated LFTs as well as concurrent management of IMP is provided in 
Section  10.6. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226068] should be 
performed as soon as possible to confirm the pregnancy. Pregnancy will lead to definitive treatment 
discontinuation in all cases. Refer to Section 1.3 for the schedule of pregnancy tests performed throughout 
this study. 
 
8.3.2 Time period and frequency for collecting AE and SAE information  
All AEs and SAEs will be collected from the signing of the ICF up to the end of study visit at the 
time points specified in the SoA ( Section  1.3), or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whiche ver comes last. 
All SAEs and AESI will be recorded and reported to the Sponsor or designee within 24 hours, as 
indicated in Appendix 3 ( Section  10.3). The Investigator will submit any updated SAE and AESI 
data to the Sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE after conclusion of the study participation. However, if the Investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and he/she considers the event to be reasonably related to the IMP or study pa rticipation, the Investigator mu st promptly notify the Sponsor. 
The method of recording, evaluating, and assessing  causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section 10.3 ). 
Adverse event (SAE and AESI) reporting is summarized in Table 7 . 
Table 7 – Adverse event reporting 
Adverse event/laboratory abnormality  Reporting timeframe 
Serious adverse event  Within 24 hours 
Pregnancy  Within 24 hours 
Overdose Symptomatic Within 24 hours 
 Asymptomatic Routine 
ALT elevation    
 ALT >[ADDRESS_1226069] and associated with  
total bilirubin >[ADDRESS_1226070] 
ALT >[ADDRESS_1226071] if baseline ALT is ≤[ADDRESS_1226072] Within 24 hours 
 
Within 24 hours 
 ALT >[ADDRESS_1226073]  if baseline ALT is >[ADDRESS_1226074] Within 24 hours 
Anaphylactic or systemic allergic reactions that require treatment. Within 24 hours 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 63 Adverse event/laboratory abnormality  Reporting timeframe 
Severe injection site reactions that last longer than 24 hours. Within 24 hours 
Infections as defined in Table 6  
Malignancy                                                                                                                                Within 24 hours Within 24 hours 
ALT: alanine aminotransaminase; ULN: upper limit of normal
. 
8.3.3 Method of detecting AEs and SAEs 
Care will be taken not to introduce bias when  detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the particip ant is the preferred method to inquire about 
AE occurrences.  
8.3.4 Follow-up of AEs and SAEs 
After the initial AE/SAE report, the Investigator is required to proactively follow each participant 
at subsequent visits/contacts.  At the pre-specified study end-date, all SAEs,  and non-serious AEs 
of special interest (as defined in Section  8.3.1),  will be followed until resolution, stabilization, the 
event is otherwise explained, or the partic ipant is lost to follow-up (as defined in Section  7.3). 
Further information on follow-up procedures is given in Appendix 3 ( Section  10.3). 
8.3.5 Regulatory reporting requirements for SAEs 
• Prompt notification by [CONTACT_46352] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
an IMP under clinical investigation are met.  
• The Sponsor has a legal responsibility to notif y both the local regulatory authority and 
other regulatory agencies about the safety of an IMP under clinical investigation. The 
Sponsor will comply with country-specific re gulatory requirements relating to safety 
reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent 
Ethics Committees (IEC), and Investigators. 
• Investigator safety reports must be prepar ed for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory requirements and Sponsor policy and 
forwarded to Investigators. 
• An Investigator who receives an Investigator safety report describing a SAE or other specific safety information (eg, summary or listing of SAEs) from the Sponsor will review and then file it along with the Investigator’s Brochure and will notify the IRB/IEC, if appropriate according to  local requirements. 
8.3.6 Pregnancy 
See AESI ( Section  8.3.1). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 64 8.3.7 Disease-related events and/or disease-related outcomes not qualifying as AEs or 
SAEs 
In this study, some AEs are considered related to the underlying condition and thus will not be 
considered unexpected. Specifically, for patients w ith COPD worsening of underlying condition is 
not considered an AE unless it meets serious criteria as defined in Appendix 3 ( Section  10.3). 
Any other AE not listed as an expected event in the IB or in this protocol will be considered unexpected. 
  
8.3.[ADDRESS_1226075] complaints / medical device incidents (including 
malfunctions) 
Any defect in the IMP/NIMP/device must be report ed as soon as possible by [CONTACT_400728] a pr oduct complaint form w ithin required timelines. 
Appropriate information (eg, samp les, labels or documents like pi[INVESTIGATOR_12989]) related to 
product identification and to the potential deficiencies may need to be gathered. The Investigator will assess whether or not the quality issue has to be reported together with an AE or SAE. 
8.4 TREATMENT OF OVERDOSE 
Symptomatic overdose of IMP is an AESI (defined in Section  8.3.1). No antidote is available for 
SAR440340. 
In the event of an overdose, the Investigator/treating physician  should: 
1. Contact [CONTACT_27465]. 
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities. 
3. Obtain a serum sample for PK analysis as s oon as possible, from the date of the last dose 
of IMP if requested by [CONTACT_1689] (determined on a case-by-case basis). 
4. Document the quantity of the excess dose as well as the duration of the overdose in the 
CRF. 
8.5 PHARMACOKINETICS 
Blood samples will be collected for determination of functional SAR440340 in serum as specified 
in the SoA ( Section  1.3). Samples may be collected at additional time points during the study if 
warranted (see Appendix 6, Section  10.6).  Special procedures for collection, storage, and 
shippi[INVESTIGATOR_209408]. The actual date and time (24-hour clock time) of each samp le will be recorded.  
For patient(s) who have consented to it, the samp les that are archived, unused or left over after 
planned testing may be used for additional research purposes (Appendix 16, see Section  10.17). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 65  
Table 8 - Summary of handling procedures for pharmacokinetic (PK) samples 
Sample type PK (SAR440340) 
Matrix Serum 
Blood sample volume 5 mL 
Anticoagulant None 
Blood handling procedures See Operational Manual 
Serum aliquot split 2 aliquots  
Serum shipment condition In dry ice 
PK = pharmacokinetics. 
 
The bioanalytical methods for pha rmacokinetics are summarized in Table 9 . 
Table 9 - Summary of bioanalytical methods for pharmacokinetics samples 
Analyte PK (SAR440340) 
Matrix Serum 
Analytical technique ELISA 
Site of bioanalysis Regeneron 
ELISA: enzyme-linked immunosorbent assay; PK: pharmacokinetics. 
 Drug concentration information that may unblind the study will not be reported to investigative 
sites or blinded personnel until the study has been unblinded. 
Note: If an SAE or AESI (anaphylaxis, hypersensitivities, ISR, or certain laboratory abnormalities [see appendix 6,  Section  10.6]) occur in a patient, blood samples should be collected for 
determination of functional SAR440340 concentration, and ADA a ssessment at or near the onset 
and completion of the occurrence of the event, if possible. The exact date and time of sample collection must be recorded and entered into the database by [CONTACT_2237]. An unscheduled systemic drug concentration page in the eCRF must be completed as well. If 
necessary for safety monitoring, additional ADA samples may be collected after the EOS Visit 
until resolution of AE. 
Specifically for PK, any changes in the timing or addition of time points for any planned study 
assessments must be documented and approved by [CONTACT_877387], but will not constitute a protocol amendment. The IRB/IEC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICF. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 66 8.6 PHARMACODYNAMICS 
8.6.1 Pharmacodynamic variables/Biomarkers   
• Blood eosinophil and neutrophil counts. 
• Induced sputum for RNA expression (optiona l for patients at a subset of sites). 
• Selected biomarkers of the IL-33 a nd/or Type [ADDRESS_1226076]  
- Total IL-33, soluble IL-33 receptor (sST2),  
- Calcitonin 
- PARC 
- Eotaxin-3 
- Total IgE. 
- Fibrinogen 
• Optional: Messenger ribo nucleic acid sequencing or whole transcriptome analysis.  
• Optional: DNA/RNA sample will be collected for pharmacogenomic effects ( Section  8.7). 
For timing of PD sample collection refer to SoA ( Section  1.3) 
Assay methodologies are briefly summarized below. More detaile d information on the collection, 
handling, transport, and preservation of sa mples (eg, minimum volumes required for blood 
collection and for aliquots for ea ch biomarker assay) will be pr ovided in a separate laboratory 
manual. 
Specific procedures for coll ection, storage and shippi[INVESTIGATOR_877347] a lab manual. 
8.6.[ADDRESS_1226077] 5-part WBC 
differential cell count on a hema tology auto analyzer.  Blood eosinophil and neutrophil counts 
will be measured at timepoints additional to hematology (see Section  1.3). 
8.6.3 Plasma/serum biomarkers 
Total IL-33, sST2, PARC will be assayed using a validated enzyme immunoassay.  
Calcitonin assay: (development  of assay method ongoing). 
Fibrinogen assay: (development of immunoassay method ongoing). 
Eotaxin-[ADDRESS_1226078] asma with a validated enzyme immunoassay.  
Total IgE will be measured with a quantitative method (eg, Phadia I mmunoCAP) approved for 
diagnostic testing. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226079] be obtained 
before sampling. 
For those patients who consent to the optional pharmacogenomic sample coll ection section of the 
ICF, blood samples for exploratory genetic analysis of DNA or RNA (See Appendix 5: 
Pharmacogenomics, Section  10.5) will be collected at the study visit as specified in the SoA 
(Section 1.3 ), and these samples will be stored for future analysis(Appendix 16: Future use of 
samples, see Section  10.17). Specific procedures for coll ection, storage and shippi[INVESTIGATOR_877348] a lab manual.  For patient(s) who have consented to it, the samp les that are archived, unused or left over after 
planned testing may be used for additional research purposes ( Section  10.17). 
In the event of DNA extraction failure, a repl acement genetic blood sample may be requested 
from the participant.   
8.8 BIOMARKERS 
Pharmacodynamic and pharmacogenomic  biomarkers are described in Section  8.6 and 
Section 8.7 , respectively. 
8.8.1 Immunogenicity assessments 
Blood samples will be collected for determina tion of antibodies to SAR440340 in serum as 
specified in the SoA (Section  1.3). Blood samples should be collected at the final visit from 
participants who discon tinued IMP or were withdrawn from the study.  Samples may be collected 
at additional time points during the study if warranted (see Appendix 6, Section  10.6). Special 
procedures for the collection and handling of samp les will be provided by [CONTACT_1034]. The actual 
date and time (24-hour clock time) of each sample will be recorded. 
Table 10 - Summary of handling procedures for antidrug antibody (ADA) samples 
  
      Sample type ADA (SAR440340) 
Matrix Serum 
Blood sample volume 5 mL 
Anticoagulant None 
Blood handling procedures See Operational Manual 
Serum aliquot split 2 aliquots  
Serum shipment condition In dry ice 
ADA = antidrug antibodies 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 68 The bioanalytical method for antidrug antibody is summarized in Table 11 . In a patient with 
treatment-emergent ADA response, if the sample at week 12 is positive in the ADA assay, then 
ADA assessments may be performed on PK samples collected at Week 4. 
Table 11 - Summary of bioanalytical methods antidrug antibody 
Analyte ADA (SAR440340) 
Matrix Serum 
Analytical technique ELISA/Electrochemiluminescence 
Site of bioanalysis Regeneron 
ADA = antidrug antibodies; ELISA: enzyme-linked immunosorbent assay 
Note: If an SAE or AESI (anaphylaxis, hypersen sitivity, or an ISR lasting more than 24 hours) 
occurs in a patient, blood samples should be colle cted for ADA assessment at or near the event. 
The exact date and time of sample collection must be recorded and entered into the database by 
[CONTACT_2237]. An unscheduled page in th e eCRF must be complete d as well. If necessary 
for safety monitoring, additional ADA labs may be drawn after the EOS Visit until resolution of AE. 
8.9 HEALTH ECONOMICS 
Health economics and patie nt related outcome ( Section  8.1.2]) data, associated with medical 
encounters, will be collected in the PRO questionnaires (see Section  8.1.2) by [CONTACT_67834]-site personnel for all participants throughout the study. Prot ocol-mandated procedures, tests, 
and encounters are excluded from the PRO questionnaires.  
When completed at study site, PRO assessments should be completed as part of the visit (per 
study flow chart) but prior to any meaningful communication with a health care professional or 
any other study procedures. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226080] that SAR440340 is superi or to placebo at the two-sided 5% alpha level:  
H0: Rate ratio of SA R440340 versus placebo ≥1 versus Ha: Rate  ratio of SAR440340 
versus placebo <1.  
The statistical hypothesis for the key secondary  efficacy endpoint, the change from baseline to 
Week 16-[ADDRESS_1226081]  that SAR440340 is superior to placebo at the 
two-sided 5% alpha level: 
H0: The change in the SAR440340 group is not larger than that in the placebo group 
versus Ha: The change in the SAR440340 group is larger than that in the placebo group. 
9.2 SAMPLE SIZE DETERMINATION  
To assess the power of the primary efficacy endpo int the annualized rate of moderate-to-severe 
AECOPD, we assume 
• Average of 1.0 to 1.5 AECOPD per year in the placebo group of this study population 
enriched for severity and high risk of AECOPD.  
• The number of AECOPD follows a negative binomial distribution with dispersion parameter 1.5 ( 8) for all the groups. 
• A Wald-test is used to test whether the risk ra tio is 1 with 2-sided 5% significance level.  
• Patients will be treated with a minimum of 24 weeks and a maximum of 52 weeks depending on their study entry times. The monthly cumulative patient accruals are assumed to be 1, 5, 10, 25, 50, 90, 150, 210, 270, 335 and 340 for an eleven (11)-month accrual period.    
• Cumulatively, 9%, 15% and 20% of patients drop out of the study due to discontinuation 
or other reasons by 12, 24 and 52 weeks after study entry.  
• Patients are randomized to the treatment group and the placebo group with a 1:1 ratio. 
With these assumptions and 170 patients per group  (340 patients in total), the study will yield 
81.6% to 88.8% powers with risk re duction equal to 45% and the plac ebo rate ranging from 1.[ADDRESS_1226082] 80% power, th e minimum risk reduction is from 44.2% to 40.6%. 
The minimum detectable risk reduction (i.e. w ith 50% power) is from 32.7% to 30.0%. See the 
table below for more details.    
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 70 Table 12 - Power calculation for various event rates in the placebo group 
 Power for certain Risk Reduction (RR) Minimum RR for certain power 
Placebo rate RR=40% RR=45% RR =50% Power=80% Power=50% 
1.0 69.9% 81.6% 90.3% 44.2% 32.7% 
1.2 74.1% 85.2% 92.9% 42.5% 31.4% 
1.5 78.5% 88.8% 95.2% 40.6% 30.0% 
RR: risk reduction 
Based on the accrual and drop-out assumptions, the mean exposure time is 35.5 (±12.8) weeks. 
Since we use variable follow-up times for patients entering at different times, the power will 
depend on the actual accrual rates and the drop-out rates. We will closely monitor these rates. If the accrual rates are significantly lower than planned and/or the drop-out rates are higher than expected, the minimum treatment period may be ex tended to achieve the de sired amount of total 
exposure. The maximum treatment period of [ADDRESS_1226083]-bronchodilator FEV 1, we assume that: 
• A common standard deviation of 0.3 L in each  of the two groups is assumed, which is a 
consensus value based on the review of  historical data from COPD trials. 
• A difference of 0.12 L between the treatment group and the placebo group. 
• A 2-sided t-test with 5% significance level. 
• Fifteen percent (15%) of patients with missing  data at Week 24 due to discontinuation or 
other reasons.  
• Patients are randomized to the treatment group and the placebo group with a 1:1 ratio. 
With these assumptions and 170 patients per group  (340 patients in tota l), we will have 92.6% 
power to detect the difference of 0.[ADDRESS_1226084] ratified by [CONTACT_6674]/Visit 1 eosinophil count (see below) and by 
[CONTACT_1606].  To ensure scientific validity, alerts will be built into the inte ractive voice/web response system 
(IVRS/IWRS) to control the number of patients enrolled into each stratification groups, as 
follows: 
1. Eosinophil <250 /mm
3: approximately 50 % (170) patients  
2. Eosinophil ≥250 /mm3: approximately 50 % (170) patients. 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 71  
9.3 POPULATIONS FOR ANALYSES 
For purposes of analysis, the following populations are defined ( Table 13 ): 
Table [ADDRESS_1226085] 
randomization will be used in any analysis population. The safety experience 
associated with any later randomization will be assessed separately.  
Modified Intent-to-treat (mITT) The analysis population for the efficacy endpoints will be the modified intent-to-treat 
(mITT) population: all randomized patients who received at least [ADDRESS_1226086] 1 
injection of IMP.  
For safety analyses, patients will be analyzed in the treatment group for which they 
received the majority of injections. 
Pharmacokinetic (PK) The PK population will consist of all patients in the mITT population with at least 1 
postdose, nonmissing SAR440340 serum concentration. 
Antidrug antibody (ADA) The ADA population will consist of all patients in the mITT population with at least one 
qualified result in the anti-SAR440340 assay following the first dose of study 
medication. Patients will be analyzed according to the treatment actually received. 
ICF: informed consent; mITT: modified intent-to-treat; PK:pharmacokinetic; ADA: antidrug antibody. 
9.4 STATISTICAL ANALYSES 
The statistical analysis plan will be developed and finalized before database lock and will describe 
the participant populations to be  included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. This section is  a summary of the planned statistical analyses 
of the primary and secondary endpoints. 
9.4.1 Efficacy analyses 
All efficacy analyses will be performed on the mITT population, unless otherwise specified. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 72 Table 14 - Efficacy analyses 
Endpoint Statistical Analysis Methods 
Primary  
Rate of moderate-to-severe 
AECOPD over 52 weeks. For the primary efficacy endpoint, the annualized exacerbation rate, a negative binomial 
regression model will be used to assess treatment  differences. The model will include the total 
number of events occurring during the observation per iod (up to Week 52) as response variable, 
and the treatment group, the baseline eosinoph il strata and region (pooled countries) as 
covariates. Log-transformed observation duration will be the offset variable. Parameters will be 
estimated using the maximum likelihood me thod with the Newton-Raphson algorithm.  
The annualized event rate for each of the treatment groups and the ratio between the treatment 
and placebo along with its 95% confidence interv al will be estimated from the model.  
In the case of premature discontinuation of study drug, a secondary analysis will include events 
up to [ADDRESS_1226087] dose. 
Using the same method, subgroup analyses wil l be performed separately by [CONTACT_877358] ( ≥250 /mm3 versus <250 /mm3). 
Secondary  
Key Secondary 
• Change from baseline 
in FEV1 to Week 16-24 (pre-
bronchodilator*)  
 
 
  
 
 
 
   Key Secondary Endpoint The key secondary efficacy endpoint, the average change from baseline to Week 16-[ADDRESS_1226088] model with repeated measures 
(MMRM) approach. Model-based averages ac ross Weeks 16, 20 and 24 will be compared 
between the treatment groups. The dependent variabl e is the change from baseline in pre-
bronchodilator FEV1 at each time points. The m odel will include baseline FEV1 value, treatment 
group, visit, and treatment-by-visit interaction, the baseline eosinophil strata, and region (pooled 
countries), as covariates. An unstructured correlation matrix will be used to model the within-
patient correlations. Parameters will be estima ted using restricted maximum likelihood method 
with the Newton-Raphson algorithm. Additional cova riates such as the background medications, 
age, height, gender, race and smoking status will be considered for inclusion in the analysis 
model based on evaluation of blinded data and the final analysis model documented in the 
statistical analysis plan (SAP). 
Comparison between the treatment group and t he placebo group will be made within this model 
and the least square mean difference and their 95 % confidence intervals will be estimated. 
In the case of premature discontinuation of study drug the primary analysis will include data up 
to [ADDRESS_1226089] dose. 
Subgroup analyses will be performed using the sa me method by [CONTACT_877359] 
(≥250 /mm
3 versus <250 /mm3) 
Other Secondary 
• Change from baseline 
in FEV1 to Week 24  (post-bronchodilator*)  
• Time to first moderate or severe AECOPD 
 
 
 Other secondary endpoints 
Change from baseline to Week [ADDRESS_1226090] Week 
24 in FEV1 (both pre-bronchodilator and post-bronchodilator).   Time to first moderate or severe AECOPD will be analyzed using a Cox regression model with 
treatment, baseline eosinophil strata, and region (pooled country) as covariates. The Kaplan-
Meier (K-M) method will be used to estimate the probabilities of first AECOPD at specific time 
points for each group. Additional  covariates will be considered based on evaluation of blinded 
data and the final analysis model documented in the SAP. 
Exploratory Will be described in the statis tical analysis plan finalized before database lock 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 73 9.4.2 Safety analyses 
The summary of safety results will be presented by [CONTACT_63300]. All safety analyses will be 
performed on the mITT population using the following common rules: 
The baseline value is defined generally as the last  available value before the first dose of IMP.  
Table 15 - Safety analyses 
Endpoint Statistical Analysis Methods 
AE, SAE, AE 
leading to 
discontinuation Adverse event incidence tables will present by [CONTACT_2942] (SOC) (sorted by [CONTACT_208562]), high-level group term (HLGT), high level term (HLT) and preferred term (PT) sorted in alphabetical 
order for each treatment group, the number (n) and perc entage (%) of patients experiencing an AE. Multiple 
occurrences of the same event in the same patient will be counted only once in the tables within a 
treatment phase. The denominator for computation of  percentages is the safety population within each 
treatment group. 
Proportion of patients with at least one TEAE, serious  TEAE, and TEAE leading to discontinuation of the 
study will be tabulated by [CONTACT_1570]. In additi on TEAEs will be described according to maximum 
intensity and relation to the study drug. Serious AEs and AEs leading to study discontinuation that occur 
outside the treatment-emergent period will be summarized separately. 
AESI The following summaries will be generated: 
1.  Incidence of each AESI will be tabulated by [CONTACT_1570]. 2.  The time-to-first event analyzed using K-M methods and displayed as K-M plots (cumulative incidence 
(%) versus time based on K-M estimates) will be provided to depi[INVESTIGATOR_440904]. When 
TEAE start date or worsening date is partially available, the maximum of the earliest possible TEAE start date and the treatment start date will be used. When TEAE start date or worsening date is completely 
missing, the treatment start date will be used. 
3.  An overview summary of the number (%) of patients with 
- any TEAE 
- any serious AE (regardless of treatment-emergent status) 
- any treatment-emergent SAE 
- any AE leading to death 
- any TEAE leading to permanent study drug discontinuation 
- any TEAE by [CONTACT_11196], corrective treatment, and final outcome 
- cumulative incidence at specified time points (K -M estimates at Week 1, 4, 12, 24, 52 and 72) 
Definitions of AESIs and the method to identify AESIs will be specified in the SAP. 
Death The following deaths summaries will be generated: 
- Number (%) of patients who died by [CONTACT_6960] (TEAE, on-study) and reasons for death 
summarized on the safety population by [CONTACT_82153]  
- Death in nonrandomized patients or randomized and not treated patients 
- Treatment-emergent AE leading to death (death as an outcome on the AE eCRF page as reported by 
[CONTACT_737]) by [CONTACT_148274], HLGT, HLT, and PT showing number (%) of patients sorted by 
[CONTACT_179654], HLT, and PT. 
PCSA The following definitions will be applied to  laboratory parameters, vital signs, and ECG. 
- The potentially clinically significant abnormality (PCSA) values are defined as abnormal values 
considered medically important by [CONTACT_181295]/thresholds based on 
literature review and defined by [CONTACT_877388], vital signs, and ECG.  
- The PCSA criteria will determine which patients had at least 1 PCSA during the on-treatment period, 
taking into account all evaluations performed duri ng the on-treatment period, including unscheduled or 
repeated evaluations. The number of all such patient s will be the numerator for the on-treatment PCSA 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226091] to the 
baseline status will be provided. 
AE: adverse event; SAE:  serious adverse event; SOC: system organ class; HGLT: high-level group term; HLT: high 
level term; PT: preferred term; n: number; AESI: adverse event of special interest; K-M: Kaplan-Meier; SAP: statistical analysis plan; PCSA: potentially clinically significant abnormality; ECG: electrocardiogram. 
 
Patient data listings will be provided for all AEs, TEAEs, SAE, AEs leading to study 
discontinuation, AESIs, and deaths. 
9.4.[ADDRESS_1226092] an finalized before database lock.  
The population PK analysis and pharmacodynamic analyses be presented separately from the 
main clinical study report (CSR). 
 Table 16 - Other analyses 
Endpoint Statistical Analysis Methods 
Pharmacokinetics 
(PK) Concentrations of functional SAR440340 will be summa rized using arithmetic and geometric means, 
standard deviation, standard error of the mean (SEM), c oefficient of variation (CV%), minimum, median, 
and maximum by [CONTACT_181300]. 
Anti-drug antibodies (ADA) The incidence of positive ADA response for SAR440340 will be assessed as absolute occurrence (n) and percent of patients (%), presented by [CONTACT_877389]. Listing of ADA titer levels will be provided for 
patients positive in the ADA assay.  
The ADA analysis will be detailed in the SAP. 
Pharmacodynamics The values to be used as baseline will be t hose collected on Day 1 (predose assessments). If any of the 
scheduled assessments on Day 1 are technically disqual ified (eg, insufficient sample), then values 
determined at Screening can be used as baseline.  
For all parameters, raw data, absolute changes from baseline, and percent changes from baseline will be 
summarized in descriptive statistics by [CONTACT_11571].  Summary plots (mean ± standard error of the mean) on raw data, absolute changes from baseline and 
percent changes from baseline will be provided by [CONTACT_1570]. 
Patient Reported 
Outcomes (health-
related quality of life/health 
economics 
variables) Change from baseline in the following variables: EXACT, SGRQ, and EQ-5D will be analyzed with an 
MMRM approach described previously for the continuous efficacy variables. Descriptive statistics including 
number of patients, mean, standard error and LS means  will be provided. In addition, difference in LS 
means, the corresponding 95% CI’s, and the p-values will be provided for comparison between the active treatment groups and the placebo group. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 75 9.5 INTERIM ANALYSES  
No formal interim analysis is planned.  
Analyses of study data will be performed on an ongoing basis and provided to an internal DMC 
for internal decision making. No formal stoppi[INVESTIGATOR_877349]. 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 76 10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
10.1 APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS 
10.1.1 Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
- Consensus ethical principles  derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines 
- Applicable International Council for Ha rmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines 
- Applicable laws and regulations 
• The protocol, protocol amendments, ICF, I nvestigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an Institutional Review Board (IRB) 
/Independent Ethics Committee (IECs) by [CONTACT_6661]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.  
• The Investigator will be responsible for the following: 
- Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC 
- Notifying the IRB/IEC of SAEs or other si gnificant safety findings as required by 
[CONTACT_1744]/IEC procedures 
- Providing oversight of the conduct of th e study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations 
10.1.2 Informed Consent Process 
• The Investigator or his/her representative will explain the nature of the study to the participant or his/her legally authorized representative and an swer all questions regarding 
the study.  
• Participants must be informed that their participation is voluntary. Participants will be required to sign a statement of informed c onsent that meets the requirements of [ADDRESS_1226093] 
(HIPAA) requirements, where applicable , and the IRB/IEC or study center.  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 77 • The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the in formed consent must also sign the ICF. 
• Participants must be re-consented to the most current version of the ICF(s) during their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representative.  
10.1.3 Data Protection 
• Participants will be a ssigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor  will contain the identif ier only; participant 
names or any information which would make the participant identifiable will not be transferred.  
• The participant must be informed that his/her personal study-related data will be used by [CONTACT_877390]. The level of disclosure must also 
be explained to the participant.  
• The participant must be informed that his/her medical records may be examined by [CONTACT_9325], by [CONTACT_6667]/IEC members, a nd by [CONTACT_6668]. 
10.1.4 Committees Structure 
The study data will be reviewed by [CONTACT_701805]. 
[IP_ADDRESS] Data Monitoring Committee (DMC) 
An internal DMC will be comprise d of individuals with expertise in the diseases under study, 
biostatistics, or clinical research. The DMC memb ers are independent of the project/study teams 
and are not involved in the study conduct. The pr imary responsibilities of the DMC are to review 
and evaluate the study data during the course of  the trial and make a ppropriate recommendations 
regarding the conduct of the clinical trial to project/study team.    
The DMC procedures and data to be reviewed by [CONTACT_877391]. 
10.1.5 Dissemination of Clinical Study Data 
[COMPANY_011] shares information about c linical trials and results on publi cally accessible websites, based 
on company commitments, international and local legal and regulatory requirements, and other clinical trial disclosu re commitments established by [CONTACT_13174].  These 
websites include clinicaltrials.gov, EU clinicaltrialregister (eu.ctr), and sanofi.com, as well as 
some national registries. 
In addition, results from clinical trials in patients are required to be submitted to peer-reviewed 
journals following internal company review for accuracy, fair balance a nd intellectual property. 
For those journals that request sharing of the analyzable data sets that are reported in the 
publication, interested researchers are directed to submit their request to 
clinicalstudydatarequest.com. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226094] the 
privacy of participants in our clinical trials.   Details on data sharing criteria and process for 
requesting access can be found at this web address: clinicalstudydatarequest.com. 
10.1.6 Data Quality Assurance 
• All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The 
Investigator is responsible for verifying th at data entries are accurate and correct by 
[CONTACT_1189].  
• The Investigator must maintain accurate do cumentation (source data) that supports the 
information entered in the CRF.  
• The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide di rect access to source data documents.  
• The Sponsor or designee is responsible for th e data management of this study including 
quality checking of the data.  
• Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of  participants are being protected; and that 
the study is being conducted in accordance w ith the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
• Records and documents, including signed ICFs , pertaining to the conduct of this study 
must be retained by [CONTACT_682275] r 15 years after study completion unless local 
regulations or institutional policies require a longer reten tion period. No records may be 
destroyed during the retention period without  the written approval of the Sponsor. No 
records may be transferred to another locati on or party without written notification to the 
Sponsor.  
10.1.7 Source documents 
• Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source docu ments are filed at the Investigator’s site. 
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may need to reque st previous medical records or transfer 
records, depending on the study. Also, curre nt medical records must be available. 
• Definition of what constitute s source data can be found in the Study Reference Manual. 
10.1.[ADDRESS_1226095] been collected and a study-site  closure visit has been performed. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 79 The Investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in a dvance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_9330]: 
• Failure of the Investigator to comply with th e protocol, the requirements of the IRB/IEC or 
local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by [CONTACT_737] 
• Discontinuation of further IMP development. 
10.1.9 Publication Policy 
• The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the Sponsor 
before submission. This allows the Sponsor to protect proprietary information and to 
provide comments 
• The Sponsor will comply with the requirements for publication of study results. In accordance with standard edito rial and ethical practice, th e Sponsor will generally support 
publication of multicenter studies only in their en tirety and not as individual site data. In 
this case, a coordinating Investigator [INVESTIGATOR_12992] 
• Authorship will be determined by [CONTACT_23531]. 
10.2 APPENDIX 2: CLINICAL LABORATORY TESTS 
The tests detailed in Table 17  will be performed by [CONTACT_2237].  
• Local laboratory results are only required in the event that the central laboratory results are not available in time for either IMP administration and/or response 
evaluation. Additionally, if the local laborator y results are used to make either an IMP 
decision or response evaluation, the results and normal ranges must be entered into the 
CRF. 
• Protocol-specific requirements fo r inclusion or exclusion of participants are detailed in 
Section  5 of the protocol. 
• Additional tests may be performed at any time during the study as determined necessary by [CONTACT_9332]. 
 
  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 80 Table 17 - Protocol-required safety laboratory assessments 
Laboratory 
assessments  Parameters 
Hematology To include hemoglobin, hem atocrit, platelet count, total white blood cell (WBC) count with 5-part 
differential count, and total red blood cell count. N eutrophil and eosinophil counts (study biomarkers) 
will be evaluated as a part of hematology testing,  and are also evaluated at additional timepoints 
(see SoA Section 1.3). 
Clinical chemistry 
 
 To include creatinine, blood urea nitrogen, glucose, uric acid, total cholesterol, total protein, 
albumin, total bilirubin (in case of values abov e the normal range, differentiation in conjugated and 
nonconjugated bilirubin), ALT, AST, alkaline phosphat ase, lactate dehydrogenase, electrolytes 
(sodium, potassium, chloride), bica rbonate, and creatine phosphokinase. 
Routine urinalysis To include specific gr avity, pH, glucose, ketones, blood, protein, nitrate, leukocyte esterase, 
urobilinogen, and bilirubin. If any parameter on the dipstick is abnormal, a urine sample should be 
sent to the central laboratory for quantitative m easurement. If positive for protein and/or red blood 
cells, microscopic analysis will be performed by [CONTACT_2237]. Cotinine will be tested using 
the urine sample collected. 
Other tests • Clinical laboratory testing at Screening Visit 1 will include hepatitis screen covering HBs Ag, 
hepatitis B surface antibody (HBs Ab), HBc Ab, hepatitis C virus antibodies (HCV Ab), HIV 
screen (Anti-HIV-1 and HIV-2 antibodies) and anti nuclear antibody (ANA). In case of results 
showing HBs Ag (negative) and HBc Ab (positive), an HBV DNA testing may be performed 
prior to randomization to rule out a false positivity if the Investigator believes the patient is a false positive, or to clarify the serological status if  the Investigator finds it unclear to interpret in 
absence of known HBV infection. In case of results showing HCV Ab (positive), an HCV RNA testing may be performed to rule out a false positivity, if the Investigator believes the patient is 
a false positive  
Note: Anti-ds DNA antibody will be tested if ANA is positive ( ≥1:160 titer).  
• Clinical laboratory testing at Screening Visit [ADDRESS_1226096] document their review of each laboratory safety report. 
Laboratory/analyte results that could unblind the study will not be reported to investigative sites 
or other blinded personnel until the study has been unblinded. 
10.3 APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING 
DEFINITION OF AE 
AE definition 
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of IMP, wh ether or not considered related to the IMP. 
• NOTE: An AE can therefore be any unfavo rable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of IMP. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 81 Events meeting  the AE definition 
• Any abnormal laboratory test resu lts (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiol ogical scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the Investigator (ie, not re lated to progression of underlying 
disease, Section  8.3.7). 
• Exacerbation of a chronic or intermittent pr e-existing condition including either an 
increase in frequency and/or intensity of the condition 
• New conditions detected or diagnosed afte r IMP administration even though it may have 
been present before the start of the study 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction 
• Signs, symptoms, or the clinical sequelae of  a suspected overdose of either IMP or a 
concomitant medication 
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition of an AE or SAE  
• The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition of an AE or SAE. Also, "lack of efficacy" or "failure of expected pharmacological action" also constitutes an AE or SAE.  
Events NOT meeting the AE definition 
• Any clinically significant abnormal laborat ory findings or other abnormal safety 
assessments which are associated with th e underlying disease, unless judged by [CONTACT_13142]’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more se vere than expected for the participant’s 
condition (see Section  8.3.7). 
• Medical or surgical procedure (eg, endoscopy , appendectomy): the condition that leads to 
the procedure is the AE 
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]) 
• Anticipated day-to-day fluctuations of pre-ex isting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen  
DEFINITION OF SAE 
If an event is not an AE per definition above, th en it cannot be an SAE even if serious conditions 
are met (eg, hospi[INVESTIGATOR_1080]/symptoms  of the disease under study, death due to 
progression of disease). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: [ADDRESS_1226097] medical occurrence that, at any dose: 
a) Results in death 
b) Is life-threatening 
The term 'life-threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe. 
c) Requires inpatient hospi[INVESTIGATOR_877350], hospi[INVESTIGATOR_19949] (usually involving at least an overnight stay) at th e hospi[INVESTIGATOR_12332]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_1916]” occurred or was necessary, the AE 
should be considered serious. 
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is not considered an AE. 
d) Results in persistent disability/incapacity 
- The term disability means a substantial di sruption of a person’s ability to conduct 
normal life functions. 
- This definition is not intended to include  experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankl e) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption. 
e) Is a congenital anomaly/birth defect 
f) Other situations: 
- Medical or scientific judgme nt should be exercised in deciding whether SAE reporting 
is appropriate in other situa tions such as important medical events that may not be 
immediately life-threatening or result in death or hospi[INVESTIGATOR_877351]. These events should usually be 
considered serious.  
Note: The following list of medically important events is intended to serve as a guideline for determining which condition has to be considered a medically important event. The list is not intended to be exhaustive: 
• Intensive treatment in an emergency room or at home for:  
- Anaphylaxis (refer to Section  10.10 for the definition of anaphylaxis) 
- Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow aplasia, 
myelodysplasia, pancytopenia, etc).  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 83 • Convulsions (seizures, epi[INVESTIGATOR_002], epi[INVESTIGATOR_12995], etc) 
• Development of drug de pendence or drug abuse 
• ALT >3 x the upper limit of normal (ULN) + total bilirubin >[ADDRESS_1226098] or 
asymptomatic ALT increase >[ADDRESS_1226099] 
• Suicide attempt or any event suggestive of suicidality 
• Syncope, loss of consciousness (except if  documented as a consequence of blood 
sampling) 
• Bullous cutaneous eruptions 
• Cancers diagnosed during the study  
• Chronic neurodegenerative diseases (newly diagnosed). 
 
RECORDING AND FOLLOW-UP OF AE AND/OR SAE 
AE and SAE recording 
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all  
documentation (eg, hospi[INVESTIGATOR_1088], la boratory reports, and diagnostics reports) 
related to the event. 
• The Investigator will then record all relevant AE/SAE information in the CRF. 
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor’s representative in lieu of completion of the AE/SAE CRF page. 
• There may be instances when copi[INVESTIGATOR_88650]’s representative. In this case, a ll participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_47957]’s representative. 
• The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of intensity 
The Investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories: 
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort and not interfering with everyday activities. 
• Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities. 
• Severe: An event that prevents normal everyday activities. An AE that is assessed as severe should not be confused with a SAE. Severe is a category utilized for rating the 
intensity of an event; and both AEs a nd SAEs can be assessed as severe. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 84 An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe. 
Assessment of causality 
• The Investigator is obligated to assess the relationship between IMP and each occurrence 
of each AE/SAE. 
• A "reasonable possibility" of a relationship conve ys that there are fact s, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
• The Investigator will use clinical judgment to determine the relationship. 
• Alternative causes, such as underlying diseas e(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to IMP administration will be 
considered and investigated. 
• The Investigator will also consult the Investigator’s Brochure (IB) and/or Product Information, for marketed produc ts, in his/her assessment. 
• For each AE/SAE, the Investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provi ded an assessment of causality. 
• There may be situations in which an SAE has occurred and the I nvestigator has minimal 
information to include in the initial report to  the Sponsor’s representative. However, it is 
very important that the Investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the Sponsor’s representative. 
• The Investigator may change his/her opi[INVESTIGATOR_9242]-up information and send a SAE follow-up report with the updated causality assessment. 
• The causality assessment is one of the criteria used when determining regulatory reporting requirements. 
Follow-up of AEs and SAEs 
• The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations  as medically indicated or as  requested by [CONTACT_1034]’s 
representative to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laborator y tests or investigations, histopathological 
examinations, or consultation with other health care professionals. 
• New or updated information will be recorded in the originally completed CRF. 
• The Investigator will submit any update d SAE data to the Sponsor/Sponsor’s 
representative within 24 hours of receipt of the information.  
REPORTING OF SAES 
SAE reporting to the Sponsor’s representativ e via an electronic data collection tool 
• The primary mechanism for reporting an SAE to  the Sponsor’s representative will be the 
electronic data collection tool. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 85 • If the electronic system is unavailable for mo re than 24 hours, then the site will use the 
paper SAE data collection tool (see next section). 
• The site will enter the SAE data into the electr onic system as soon as it becomes available. 
• After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data. 
• If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electr onic data collection tool has been taken off-
line, then the site can report this informati on on a paper SAE form (see next section) or to 
the Sponsor’s representative by [CONTACT_756]. 
• Contacts for SAE reporting can be found in the Protocol.  
SAE reporting via paper CRF (if eCRF is not available) 
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Sponsor. 
• In rare circumstances and in the absence of facsimile equipment, notification by [CONTACT_13186] a copy of the SAE data collection tool sent by [CONTACT_22855]. 
• Initial notification via telephone does not replace the need for the Investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames. 
• Contacts for SAE reporting can be found in Protocol. 
 
10.4 APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION 
 DEFINITIONS: 
Woman of childbearing potential (WOCBP) 
A woman is considered fertile following me narche and until becomin g post-menopausal unless 
permanently sterile (see below). 
Women in the following categories are not considered WOCBP 
1. Premenarchal 
2. Premenopausal female with 1 of the following: 
- Documented hysterectomy 
- Documented bilateral salpi[INVESTIGATOR_1656] 
- Documented bilateral oophorectomy 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 86 Note:  Documentation can come from the site  personnel’s: review of the participant’s 
medical records, medical examinati on, or medical history interview. 
3. Postmenopausal female 
- A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement ther apy (HRT). However, in the absence of 
[ADDRESS_1226100] discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment. 
CONTRACEPTION GUIDANCE 
Male participants 
• Male participants with female partners of childbearing potential are eligible to participate 
if they agree to ONE of the following during the protocol-defined time frame in Section  
5.1:  
- Are abstinent from penile-vaginal intercour se as their usual and preferred lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent 
- Agree to use a male condom plus partner use of a contraceptive method with a failure 
rate of <1% per year as described in Table 18  when having penile-vaginal intercourse 
with a woman of childbearing potentia l who is not currently pregnant 
• In addition male participants must refrain from donating sperm for the duration of the study and for [ADDRESS_1226101] dose of study intervention. 
• Male participants with a preg nant or breastfeeding partner must agree to remain abstinent 
from penile-vaginal intercourse or use a male condom during each epi[INVESTIGATOR_228058]-defined time frame (from the signing of the ICF until the end of study visit).  
Female participants 
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception cons istently and correctly as described in Table 18 . 
Table 18 - Highly effective contraceptive methods 
Highly effective contraceptive methods that are user dependenta 
Failure rate of <1% per year when used consistently and correctly.  
Combined (estrogen and progestogen containi ng) hormonal contraception associat ed with inhibition of ovulation  
Oral  
Intravaginal  
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 87 Transdermal 
Progestogen only hormonal contraception asso ciated with inhibition of ovulation 
• Oral 
• Injectable 
Highly effective methods that are user independenta 
Implantable progestogen only hormonal contracepti on associated with inhibition of ovulation 
• Intrauterine device (IUD) 
• Intrauterine hormone-releasing system (IUS) 
• Bilateral tubal occlusion 
Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the 
WOCBP and the absence of sperm has been confirmed. If not, an addi tional highly effective method  of contraception should be 
used. 
Sexual abstinence  Sexual abstinence is considered a highly effective method only if defined as refraining from het erosexual intercourse during th e 
entire period of risk associated with the study intervention. T he reliability of sexual abstinence needs to be evaluated in rel ation to 
the duration of the study and the preferr ed and usual lifestyle of the participant.  
NOTES:  
a Typi[INVESTIGATOR_35818]. Use should be consistent with local regul ations 
regarding the use of contraceptive methods for participants participating in clinical studies.  
 
PREGNANCY TESTING: 
• WOCBP should only be included after a confir med menstrual period a nd a negative highly 
sensitive serum pregnancy test (at screening). Urine pregnancy tests will be performed for 
for subsequent visits. 
Additional pregnancy testing should be  performed as shown in the SoA ( Section  1.3) and as 
follows. 
• Pregnancy testing will be performed whenever a menstrual cycle is missed or when pregnancy is otherwise suspected  
COLLECTION OF PREGNANCY INFORMATION:  
Male participants with partners who become pregnant  
• The Investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This applies only to male participants who receive IMP. 
• After obtaining the necessary signed informed  consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 88 submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother a nd child will be forwarded to the Sponsor. 
Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
 
Female participants who become pregnant  
• The Investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitte d to the Sponsor within 24 hours of learning of a 
participant's pregnancy. The participant will be followed to determine the outcome of the pregnancy. The Investigator will collect follow-up information on the participant and the neonate and the information will be forwarde d to the Sponsor. Generally, follow-up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indica tion for the procedure. 
• Any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any post-study pregnancy re lated SAE considered reasonably related to 
the study intervention by [CONTACT_877392]  8.3.5. While the Investigator is not obligated to actively seek this information in 
former study participants, he or she may lear n of an SAE through spontaneous reporting.  
• Any female participant who becomes pregnant while participating in the study will discontinue study intervention 
10.5 APPENDIX 5: PHARMACOGENOMICS 
The purpose of the pharmacogenomic analyses is to identify genomic associations with clinical or 
biomarker response to drug, other COPD clini cal outcome measures and possible AEs.  In 
addition, associations between genomic variants and prognosis or progression of COPD as well 
as related allergic/atopic diseases may also be st udied. These data may be used or combined with 
data collected from other studies to identify and validate genomic markers related to the study drug or COPD and related diseases.  
Analyses may include sequence determination or  single nucleotide polymorphism studies of 
candidate genes and surrounding  genomic regions.  Other methods, including whole-exome 
sequencing, whole-genome se quencing, DNA copy number va riation, and transcriptome 
sequencing (or other methods for quantitating RNA expression) may also be performed.  The list 
of methods may be expanded to include novel methodology that may be developed during the 
course of this study or sample  storage period.  Results from the genomic analyses will not be 
reported in the CSR.   
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 89 10.6 APPENDIX 6: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND FOLLOW-
UP ASSESSMENTS  
Neutrophils < 1500/mm3or according to ethnic 
groupNEUTROPENIA
Repeat immediately a full blood count if value 
close to 1500/mm3
Neutrophils < 1500/mm3confirmed 
with signs of infection  Neutrophils < 1500/mm3confirmed 
with no signs of infection  
1. DISCONTINUE
Investigational Medicinal 
Product, hospi[INVESTIGATOR_26596]
2. PERFORM biological 
investigations for infection1. DISCONTINUE
Investigational Medicinal Product
2. INVESTIGATE for 
infection
In both situations
3. INFORM the local monitor
4. INVESTIGATE previous treatments particularly long-term, even a long time ago, 
exposure to toxic agents, e.g., benzene, X-rays, etc.
5. PERFORM and collect the following investigations (results): 
• RBC and platelet counts
• Serology: EBV , (HIV), mumps, measles, rubella
6. DECISION for bone marrow aspi[INVESTIGATOR_1516]: to be taken in specialized unit
7. COLLECT/STORE one sample following handling procedures described in PK 
sections (for studies with PK sampling) and freeze one serum sample (5 mL) on 
Day 1 (cessation of investigational medicinal product) and Day 5 (for further 
investigations)
8. MONITOR the leukocyte count [ADDRESS_1226102] one  week, then twice a 
month until it returns to normal
Note : 
•The procedures described in the above flowchart are to be discussed with the patient only in case 
the event occurs. If applicable (according to local regulations), an additional consent (e.g., for 
HIV testing) will only be obtained in the case the event actually occurs.
•For individuals of African descent, the relevant value of concern is <1000/mm3 
Neutropenia is to be recorded as an AE only if  at least 1 of the criteria listed in the general 
guidelines for reporting adverse events in Section  10.3  is met. 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 90 Platelets < 100 000/mm3(rule out EDTA – induced 
pseudo-thrombocytopenia)THROMBOCYTOPENIA
Repeat immediately the count (rule out EDTA 
anticoagulant in the sample)
Platelets  < 100 000/mm3confirmed 
with bleeding  Platelets  < 100 000/mm3confirmed 
with no bleeding
1. DISCONTINUE
Investigational Medicinal 
Product
2. HOSPI[INVESTIGATOR_877352]1. DISCONTINUE
Investigational Medicinal Product
2. INVESTIGATE for 
bleeding
In both situations
3. INFORM the local Monitor
4. QUESTION about last intake of quinine (drinks), alcoholism, heparin administration
5. PERFORM or collect the following investigations: 
• Complete blood count, schizocytes, creatinine• Bleeding time and coagulation test (fibrinogen, INR or PT, aPTT), Fibrin 
Degradation Product
• Viral serology: EBV , HIV , mumps, measles, rubella
6. COLLECT/STORE one sample following handling procedures described in PK 
sections (for studies with PK sampling) and freeze one serum sample (5 mL) on 
Day 1 (cessation of investigational medicinal product) and Day 5 (for further investigations)
7. DECISION for bone marrow aspi[INVESTIGATOR_1516]: to be taken in specialized unit
• On Day 1 in the case of associated anemia and/or leukopenia• On Day 8 if platelets remain < 50 000/mm
[ADDRESS_1226103] one week and then regularly 
until it returns to normal
Note : 
The procedures above flowchart are to be discussed with the patient only in case described in the 
the event occurs. If applicable (according to local regulations), an additional consent (e.g., for 
HIV testing) will only be obtained in the case the event actually occurs. 
Thrombocytopenia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting adverse events in Section  10.3  is met. 
 
 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 91  
 
*If unable to retest in 72 hours, use original lab result s to decide on further reporting/monitoring/discontinuation. 
• “Baseline” refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before the 
baseline visit. The algorithm does not apply to t he instances of increase in ALT during screening. 
• See Section  10.3 and Table 7 for guidance on safety reporting. 
• Normalization is defined as ≤ ULN or baseline value, if baseline value is >ULN. 
 
Note: In case of SUSPI[INVESTIGATOR_155075], a DNA diagnostic test should be done. 
 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 92 Rapid increase in serum creatinine over 150 µmol/L 
or rapid decrease in creatinine clearance below
50 mL/mnINCREASE IN SERUM CREATININE
Can be rapi[INVESTIGATOR_21352]:
•B y  v o l u m e  r e p l e t i o n• Or relief of urinary tract 
obstruction (according to etiology)Cannot be rapi[INVESTIGATOR_21352]: • Occurrence/aggravation of life 
threatening symptoms of ARF: anemia, 
hyperkalemia, hyperuricemia, metabolic 
acidosis, cardiac insufficiency, 
pulmonary edema, arrhythmia, DIC, etc.
• And/or predominant elimination of 
investigational medicinal product by [CONTACT_400751]
1. Investigational medicinal 
product may be continued
2. MONITOR serum creatinine 
until return to baseline level1. INFORM the local monitor
2. DISCONTINUE
investigational medicinal product 
administration
3. HOSPI[INVESTIGATOR_877353]
4. PERFORM the following 
examinations: 
• BP, HR, hydration status, ECG
• Blood count
• Liver function tests + CPK
• Biochemistry, including urea
•U r i n a l y s i s
5. COLLECT/STORE one sample 
following handling procedures described in PK sections (for studies 
with PK sampling) and freeze one 
serum sample (5 mL) on Day 1 (cessation of investigational 
medicinal product)
6. MONITOR renal function until 
return to baseline level (every day at 
the beginning, then every week)
 
Increase in serum creatinine is to be recorded as an AE only if at least 1 of the criteria listed in the 
general guidelines for reporting adverse events in Section  10.3  is met. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 93 If Increase in CPK (expressed in ULN)
> [ADDRESS_1226104]
Repeat immediately the count.
If confirmed, inform the local monitor and
INVESTIGATE for the origin:
-P E R F O R M :
•E C G
• CPK-MB -MM • Troponin• Creatinine• Iono (k+, Ca
2+)
• Transaminases + Total and conjugated bilirubin• Myoglobin (serum and urines)
- COLLECT/STORE one sample following handling procedures described in PK sections (for 
studies with PK sampling) and freeze one serum sample (5 mL) on Day 1 (cessation of 
investigational medicinal product). 
- INTERVIEW the patient about a recent intensive muscular effort, trauma, convulsions, electrical 
injury, injury or stress to the skeletal muscle, multiple intramuscular injections, recent surgery, concomitant medications, consumption of alcohol, morphine, cocaine.
-S E A R C H  for alternative causes to cardiac or muscular toxicity, ie, stroke, pulmonary infarction, 
dermatomyositis or polymyositis, convulsions, hypothyroidism, delirium tremens, muscular dystrophies.
If either the cardiac origin or the 
rhabdomyolysis is confirmed or if CPK 
> [ADDRESS_1226105]:
1. DISCONTINUE investigational 
medicinal product administration
2. MONITOR CPK every [ADDRESS_1226106] 3 months
3. HOSPI[INVESTIGATOR_759807] ≤[ADDRESS_1226107]:
MONITOR CPK every [ADDRESS_1226108] 3 monthsMuscular symptoms (myalgia, pain, weakness, 
dark urines)Systematic CPK assessment as per 
protocol
Perform CPKINCREASE IN CPK SUSPECTED TO BE OF NON-CARDIAC ORIGIN 
AND NOT RELATED TO INTENSIVE PHYSICAL ACTIVITY
 
Increase in CPK is to be recorded as an AE only if at least 1 of the criteria in the general 
guidelines for reporting adverse events in Section  10.3 is met. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 94 10.7 APPENDIX 7: LIST OF PROHIBITED LIVE ATTENUATED VACCINES  
• Bacillus Calmette-Guérin (BCG) antituberculosis vaccine 
• Chickenpox (Varicella) 
• Intranasal influenza (FluMist-Influenza); inactive influenza vaccine delivered by [CONTACT_125497] 
• Measles (Rubeola) 
• Measles-mumps-rubella (MMR) combination 
• Measles-mumps-rubella-varicella (MMRV) combination 
• Mumps 
• Oral polio (Sabin) 
• Oral typhoid 
• Rotavirus 
• Rubella 
• Smallpox (Vaccinia) 
• Varicella Zoster (shingles) 
• Yellow fever 
This list is indicative and not exhaustive. 
10.8 APPENDIX 8: COUNTRY-SPECIFIC REQUIREMENTS  
Not applicable 
10.9 APPENDIX 9: ABBREVIATIONS 
 
ABECB: acute bacterial exacerbations of chronic bronchitis  
AEs: Adverse events AESI: Adverse events of special interest ALT: Alanine transaminase AST: Aspartate transaminase BMI: body mass index BP: blood pressure 
CAT: COPD Assessment Test CID: Clinically Important Deterioration COPD: Chronic obstructive pulmonary disease DMC: Data monitoring committee ECG: Electrocardiogram eCRF: electronic Case Report Form 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 95 EQ-5D: Euroqol-5Dimension 
EXACT: Exacerbations of Chronic Obstructive Pulmonary Disease Tool FEV1: Forced expi[INVESTIGATOR_3741] 1 second FVC: Forced vital capacity GSO: Global Safety Officer HIV: Human immunodeficiency virus ICF: Informed consent form 
ICH: International Council for Harmonisation ICS: Inhaled corticosteroids  
IEC: Independent Ethics Committee IL: Interleukin 
IL-33: Interleukin-33 IMP: investigationa l medicinal product 
IRB: Institutional Review Board ISR: injection site reactions(s) 
IV: Intravenous 
IVRS: Interactive Voice Response System IWRS: Interactive Web Response System LABA: Long-acting β2 adrenergic agonists 
LAMA: Long-acting muscarinic antagonist mAb: Monoclonal antibody miTT: Modified Intent-to-treat MMRM: Mixed-effect model with repeated measures NIMP: noninvestigationa l medicinal product 
PCSA: Potentially clinical ly significant abnormality 
PD: Pharmacodynamics 
PK: Pharmacokinetics 
q2w: Once in every 2 weeks  QoL: Quality of life SABA: Short-acting β agonists 
SAEs: Serious adverse events  SAP: Statistical analysis plan SC: Subcutaneous 
TB: Tuberculosis 
ULN: Upper limit of normal range 
 
10.10 APPENDIX 10: PROTOCOL AMENDMENT HISTORY 
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Tabl e of Contents (TOC). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 96 10.11 APPENDIX 11: COPD ASSESSMENT TEST 
 
 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 97 10.12 APPENDIX 12: ST. GEORGE’S RESPI[INVESTIGATOR_310830] (SGRQ) 
 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
Property of the [COMPANY_011] Group - strictly confidential Page 98 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
Property of the [COMPANY_011] Group - strictly confidential Page 99 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
Property of the [COMPANY_011] Group - strictly confidential Page 100 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
Property of the [COMPANY_011] Group - strictly confidential Page 101 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
Property of the [COMPANY_011] Group - strictly confidential Page 102 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 103 10.13 APPENDIX 13: EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE TOOL (EXACT) 
 
 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 104 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 105  
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 106 10.14 APPENDIX 14: EUROQOL QUESTIONNAIRE (EQ-5D-5L) 
 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 107  
 
(electronic  
  
1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 108 
(electronic  
 1.0)

Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 109  
10.15 APPENDIX 15: DEFINITION OF ANAPHYLAXIS 
Anaphylaxis is a serious allergic reaction th at is rapid in onset and may cause death." 
(Adapted from Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA , Branum A, et al. Second 
symposium on the definition and management of anaphylaxis:  Summary report—Second National Institute of Allergy 
and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol  2006;117: 
391-7) 
Clinical criteria for diagnosing anaphylaxis 
 
 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 110  
10.16 APPENDIX 16: LIST OF OPPORTUNISTIC INFECTIONS 
• Aspergillosis 
• Blastomyces dermatitidis (endemic in the south-eastern and south-central states US, along 
Mississippi [INVESTIGATOR_208502]) 
• Candidiasis - only systemic, extensiv e mucosal or cutaneous candidiasis. 
• Coccidioides immitis (endemic south-western US and Central and South America) 
• Cryptococcus 
• Cytomegalovirus 
• Herpes Simplex (severe/disseminated) 
• Herpes Zoster 
• Histoplasmosis (pulmonary or disseminat ed; most common tropi[INVESTIGATOR_260115]-
Ohio-Mississippi [INVESTIGATOR_208504]) 
• Listeriosis 
• Mycobacterium avium 
• Nontuberculosis mycobacteria 
• Pneumocystis pneumonia (PCP) 
• Tuberculosis (TB) 
This list is indicative and not exhaustive. 
 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential Page 111  
10.17 APPENDIX 17: FUTURE USE OF SAMPLES 
Not all of the samples collected during this study may be required for the tests planned in this 
clinical trial. For patient(s) who have consented to it, the samples that are archived, unused or left 
over after planned testing may be used for additi onal research purposes (any genetic analysis 
subject to additional consent per Section  8.7). For subjects who have consented to it, archival 
blood samples will be collected at the visits  specified in the study flow chart (see  Section 1.3). 
Additional details will be provided in the laboratory manual. 
These archived serum and plasma samples, and an y residual or leftover serum, plasma or blood 
remaining from planned laboratory work, may be used for research  purposes related to COPD or 
other respi[INVESTIGATOR_877354] (eg, exploratory biomarkers of 
disease or drug effect), pathway biology, additi onal drug safety assessmen ts or development and 
validation of bioassay methods be yond those defined in the present protocol. These samples will 
remain labelled with the same identifiers as the ones used during the study (ie, Subject ID, sample 
ID). They will be transferred to a [COMPANY_011] site (or a subcontractor site) which can be located outside of the country where the study is conducted. The Sponsor has included safeguards for protecting 
subject confidentiality and personal data ( Section  10.1.3). 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential Page 112 
 11 REFERENCES 
 
1. Global Inititiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary disease (2017 report). 2017. 
[Cited 08 March 2018]. Available from http ://goldcopd.org/wp-content/uploads/2016/12/wms-
GOLD-2017-Pocket-Guide.pdf. 
2. Adeloye D, Chua S, Lee C, Basquill C, Papa na A, Theodoratou E, et al. Global and regional 
estimates of COPD prevalence: systematic review and meta-a nalysis. J Glob Health. 2015 
Dec;5(2):020415. 
3. Guarascio AJ, Ray SM, Finch CK, Self TH. Th e clinical and economic burden of chronic 
obstructive pulmonary disease in the [LOCATION_003]. C linicoecon Outcomes Res. 2013 Jun 17;5:235-45. 
4. Brusselle GG, Bracke K, Lahousse L. Targeted therapy with inhaled co rticosteroids in COPD 
according to blood eosinophil counts. La ncet Respir Med. 2015 Jun;3(6):416-7. 
5. Aaron SD, Vandemheen KL, Fergusson D, Malta is F, Bourbeau J, Goldstein R, et al. 
Tiotropi[INVESTIGATOR_96867], Salmete rol, or Fluticasone-Salmeterol for Treatment 
of Chronic Obstructive Pulmona ry Disease: a randomized trial. Ann Intern Med. 2007 Apr 
17;146(8):545-55. 
6. Calverley PM, Rabe KF, Goehring UM, Kris tiansen S, Fabbri LM, Martinez FJ, et al. 
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet. 2009 Aug 29;374(9691):685-94. 
7. Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, et al. 
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomized, double-blind, placebo-controlled, ph ase 2a study. Lancet Respir Med. 2014 
Nov;2(11):891-901. 
8. Pavord I, Chanez P, Criner GJ, Kerstjens H, Korn S, Lugogo N, et al. Mepolizumab for 
eosinophilic chronic obstructive pulmona ry disease. N Engl J Med. [ADDRESS_1226109] 
26;377(17):1613-29. 
9. Cayrol C, Girard P. IL-33: an alarmin cytokine with crucial role s in innate immunity, 
inflammation and allergy. Curr Opin Immunol. 2014 Dec;31:31-7. 
10. By[CONTACT_868494], Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, et al. Long-term IL-33-
producing epi[INVESTIGATOR_877355]. J Clin Invest. 2013 
Sep;123(9):3967-82. 
(electronic  
  
1.0)
Amended Clinical Trial Protocol 01 
ACT15104 – SAR440340 11-Jun-2018      Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential Page 113 
 11. Kearley J, Silver JS, Sanden C, Liu Z, Berlin  AA, White N, et al. Cigarette Smoke Silences 
Innate Lymphoid Cell Functi on and Facilitates an Exacerba ted Type I Interleukin-33-
Dependent Response to Infection. Immunity. 2015 Mar 17;42(3):566-79. 
12. Kim SW, Rhee CK, Kim KU, Lee SH, Hwang HG, Kim YI, et al. Factors associated with 
plasma IL-[ADDRESS_1226110] Pulmon Dis. 2017 Jan 21;12:395-402. 
13. Global Initiative for asthma. Global Strategy for Asthma Management and Prevention (GINA 
2018). 2018. [Cited 08March 2018]. Available from  http://ginasthma.org/2018-gina-report-
global-strategy-for-asthma-mana gement-and-prevention/.   
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardization 
of spi[INVESTIGATOR_038]. Series ‘‘ATS/ERS TASK FORCE: Standardization of Lung  Function Testing"  
Edited by [CONTACT_181308] V, Crapo R, and Vi egi G. Eur Resir J. 2005 Aug;26(2):319-38. 
15. COPD assessment test [I nternet]. Available from: http://www.catestonline.org/. 
16. Gupta B and Kant S. Health Re lated Quality Of Life (Hrqol) In  COPD. The Internet Journal of 
Pulmonary Medicine. 2008;11(1). 
17. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete meas ure of health status 
for chronic airflow limitation. The St. George's Respi[INVESTIGATOR_6015]. Am Rev Respir 
Dis. 1992 Jun;145(6):1321-7. 
18. Jones PW, Quirk FH, Baveystock CM. The St George's Respi[INVESTIGATOR_6015]. Respir 
Med. 1991 Sep;[ADDRESS_1226111] B:25-31; discussion 33-7. 
19. EUroQol Group. EuroQol-a new facility for the m easurement of health-related quality of life. 
Health Policy. 1990 Dec;16(3):199-208. 
 
   
(electronic  
  
1.0)
 
 
 
  
 
 
 
 
ELECTRONIC SIGNATURES  
 
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm) 
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
   
 
  
 ACT15104 16.1.1 Amended Protocol 01
Clinical Approval
Clinical Approval
